[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fpomO8hFvo0_-kX3DB0xz_XOKXUiGIekcbkG5GkXU_aY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":37,"phaseBuckets":87,"rows":94},"Maastricht University",[6,4],"Maastricht University Medical Center",939,false,103,26,245479,22,812,[15,18,21,24,26,29,32,35],{"name":16,"count":17},"Obesity",54,{"name":19,"count":20},"Healthy",21,{"name":22,"count":23},"Insulin Resistance",19,{"name":25,"count":23},"Overweight and Obesity",{"name":27,"count":28},"Breast Cancer",18,{"name":30,"count":31},"Atrial Fibrillation",16,{"name":33,"count":34},"Sarcopenia",15,{"name":36,"count":34},"Overweight",[38,43,48,53,57,62,67,72,77,82],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT02266615","Biobank Clinical Genetics Maastricht (KG01)","2024-03","Biobanking of biomaterial for future genetic research.",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT03917303","Control Crohn Safe Trial","2024-05","Adalimumab",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT06368492","The Impact of Psilocybin on Pain in Fibromyalgia Patients","2025-12","Psilocybin",{"nctId":54,"briefTitle":55,"date":51,"intervention":56},"NCT03019471","Non Invasive Cancer Test (NICT): a Proof of Principle Study.","Isolation of tumor DNA",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT05367089","The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis Symptoms","2026-04-22","Fluconazole",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT05463757","Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study","2026-06","Vismodegib",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT05748093","Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat","2026-06-01","Cobicistat",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT06401824","Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases","2026-11-01","Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT07417059","Sex Hormones Impact on Cannabis Response","2026-12-31","Cannabis",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT04954599","Phase 1\u002F2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI","2027-02","CP-506",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,127,145,167,193,211,235,253,287,310,337,363,387,405,423,443,463,481,507,528,550,583,601,650,678,696,714,740,766,793,811,836,864,882,910,928,954,981,1004,1027,1051,1069,1095,1113,1138,1156,1182,1209,1227,1251,1277,1295,1322,1340,1365,1383,1409,1427,1454,1483,1501,1519,1544,1567,1594,1619,1644,1671,1694,1717,1743,1771,1801,1819,1837,1855,1879,1904,1929,1947,1965,1989,2017,2035,2060,2078,2101,2126,2151,2199,2233,2255,2280,2298,2325,2343,2361,2386,2409,2434,2452,2476,2501,2525,2549,2577,2595,2623,2641,2659,2683,2709,2732,2757,2781,2805,2828,2853,2887,2921,2955,2981,2999,3023,3050,3075,3098,3120,3144,3169,3187,3211,3235,3262,3280,3298,3322,3348,3366,3390,3408,3431,3458,3483,3501,3526,3548,3571,3594,3620,3644,3668,3693,3716,3738,3772,3790,3808,3826,3844,3862,3886,3904,3931,3949,3967,3985,4003,4028,4046,4068,4094,4112,4134],{"intervention":96,"totalTrials":97,"cells":98},"Fluorometholone 0.1% Oph Susp",1,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":108,"NA":125},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[],{"trials":105,"activeCount":101},[],{"trials":107,"activeCount":101},[],{"trials":109,"activeCount":97,"soonestReadout":115},[110],{"nctId":111,"briefTitle":112,"status":113,"phases":114,"primaryCompletion":115,"completion":116,"start":117,"enrollment":118,"conditions":119,"interventions":123},"NCT05716945","The OPTIMISE Study","RECRUITING",[92],"2028-09","2029-03","2024-07-29",342,[120,121,122],"Pseudophakic Bullous Keratopathy","Fuchs' Endothelial Dystrophy","Intraocular Pressure",[96,124],"Dexamethasone 0.1% ophthalmic suspension",{"trials":126,"activeCount":101},[],{"intervention":124,"totalTrials":97,"cells":128},{"EARLY_PHASE1":129,"PHASE1":131,"PHASE2":133,"PHASE3":135,"PHASE4":137,"NA":143},{"trials":130,"activeCount":101},[],{"trials":132,"activeCount":101},[],{"trials":134,"activeCount":101},[],{"trials":136,"activeCount":101},[],{"trials":138,"activeCount":97,"soonestReadout":115},[139],{"nctId":111,"briefTitle":112,"status":113,"phases":140,"primaryCompletion":115,"completion":116,"start":117,"enrollment":118,"conditions":141,"interventions":142},[92],[120,121,122],[96,124],{"trials":144,"activeCount":101},[],{"intervention":71,"totalTrials":97,"cells":146},{"EARLY_PHASE1":147,"PHASE1":149,"PHASE2":151,"PHASE3":153,"PHASE4":155,"NA":165},{"trials":148,"activeCount":101},[],{"trials":150,"activeCount":101},[],{"trials":152,"activeCount":101},[],{"trials":154,"activeCount":101},[],{"trials":156,"activeCount":97,"soonestReadout":70},[157],{"nctId":68,"briefTitle":69,"status":113,"phases":158,"primaryCompletion":70,"completion":159,"start":160,"enrollment":161,"conditions":162,"interventions":164},[92],"2026-09-01","2024-04-01",60,[163],"Non-small Cell Lung Cancer",[71],{"trials":166,"activeCount":101},[],{"intervention":168,"totalTrials":97,"cells":169},"5FU-Calcipotriol",{"EARLY_PHASE1":170,"PHASE1":172,"PHASE2":174,"PHASE3":176,"PHASE4":178,"NA":191},{"trials":171,"activeCount":101},[],{"trials":173,"activeCount":101},[],{"trials":175,"activeCount":101},[],{"trials":177,"activeCount":101},[],{"trials":179,"activeCount":97,"soonestReadout":184},[180],{"nctId":181,"briefTitle":182,"status":113,"phases":183,"primaryCompletion":184,"completion":184,"start":185,"enrollment":186,"conditions":187,"interventions":189},"NCT06499415","Combination Therapy of 5-Fluorouracil and CALcipotriol Versus 5-Fluorouracil in the Treatment of Actinic Keratosis",[92],"2029-03-02","2024-09-04",232,[188],"Actinic Keratoses",[168,190],"5-FU 50 MG\u002FML Topical Cream",{"trials":192,"activeCount":101},[],{"intervention":190,"totalTrials":97,"cells":194},{"EARLY_PHASE1":195,"PHASE1":197,"PHASE2":199,"PHASE3":201,"PHASE4":203,"NA":209},{"trials":196,"activeCount":101},[],{"trials":198,"activeCount":101},[],{"trials":200,"activeCount":101},[],{"trials":202,"activeCount":101},[],{"trials":204,"activeCount":97,"soonestReadout":184},[205],{"nctId":181,"briefTitle":182,"status":113,"phases":206,"primaryCompletion":184,"completion":184,"start":185,"enrollment":186,"conditions":207,"interventions":208},[92],[188],[168,190],{"trials":210,"activeCount":101},[],{"intervention":47,"totalTrials":97,"cells":212},{"EARLY_PHASE1":213,"PHASE1":215,"PHASE2":217,"PHASE3":219,"PHASE4":221,"NA":233},{"trials":214,"activeCount":101},[],{"trials":216,"activeCount":101},[],{"trials":218,"activeCount":101},[],{"trials":220,"activeCount":101},[],{"trials":222,"activeCount":97,"soonestReadout":46},[223],{"nctId":44,"briefTitle":45,"status":113,"phases":224,"primaryCompletion":46,"completion":225,"start":226,"enrollment":227,"conditions":228,"interventions":231},[92],"2026-09","2019-12-23",158,[229,230],"Crohn Disease","Inflammatory Bowel Diseases",[47,232],"standard step-up care",{"trials":234,"activeCount":101},[],{"intervention":232,"totalTrials":97,"cells":236},{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":241,"PHASE3":243,"PHASE4":245,"NA":251},{"trials":238,"activeCount":101},[],{"trials":240,"activeCount":101},[],{"trials":242,"activeCount":101},[],{"trials":244,"activeCount":101},[],{"trials":246,"activeCount":97,"soonestReadout":46},[247],{"nctId":44,"briefTitle":45,"status":113,"phases":248,"primaryCompletion":46,"completion":225,"start":226,"enrollment":227,"conditions":249,"interventions":250},[92],[229,230],[47,232],{"trials":252,"activeCount":101},[],{"intervention":61,"totalTrials":254,"cells":255},2,{"EARLY_PHASE1":256,"PHASE1":258,"PHASE2":260,"PHASE3":262,"PHASE4":273,"NA":285},{"trials":257,"activeCount":101},[],{"trials":259,"activeCount":101},[],{"trials":261,"activeCount":101},[],{"trials":263,"activeCount":97,"soonestReadout":60},[264],{"nctId":58,"briefTitle":59,"status":113,"phases":265,"primaryCompletion":60,"completion":266,"start":267,"enrollment":268,"conditions":269,"interventions":272},[91],"2027-04-22","2022-08-22",252,[270,271],"Candidiasis, Vulvovaginal","Recurrent Candidiasis of Vagina",[61],{"trials":274,"activeCount":101},[275],{"nctId":276,"briefTitle":277,"status":278,"phases":279,"primaryCompletion":280,"completion":281,"start":282,"enrollment":268,"conditions":283,"interventions":284},"NCT04626258","Fluconazol Versus Medical Honey in the Treatment of Recurrent Vulvovaginal Candidiasis","UNKNOWN",[92],"2024-03-01","2025-03-01","2021-03-01",[270,271],[61],{"trials":286,"activeCount":101},[],{"intervention":76,"totalTrials":97,"cells":288},{"EARLY_PHASE1":289,"PHASE1":291,"PHASE2":293,"PHASE3":304,"PHASE4":306,"NA":308},{"trials":290,"activeCount":101},[],{"trials":292,"activeCount":101},[],{"trials":294,"activeCount":97,"soonestReadout":75},[295],{"nctId":73,"briefTitle":74,"status":113,"phases":296,"primaryCompletion":75,"completion":297,"start":298,"enrollment":299,"conditions":300,"interventions":303},[90],"2027-04-01","2025-04-24",25,[301,302],"NSCLC Stage IV","Brain Metastases, Adult",[76],{"trials":305,"activeCount":101},[],{"trials":307,"activeCount":101},[],{"trials":309,"activeCount":101},[],{"intervention":311,"totalTrials":97,"cells":312},"Tarlatamab",{"EARLY_PHASE1":313,"PHASE1":315,"PHASE2":317,"PHASE3":331,"PHASE4":333,"NA":335},{"trials":314,"activeCount":101},[],{"trials":316,"activeCount":101},[],{"trials":318,"activeCount":97,"soonestReadout":324},[319],{"nctId":320,"briefTitle":321,"status":322,"phases":323,"primaryCompletion":324,"completion":325,"start":326,"enrollment":327,"conditions":328,"interventions":330},"NCT07402343","Tarlatamab for SCLC Brain Metastases","NOT_YET_RECRUITING",[90],"2029-02","2030-02","2026-05",35,[329,302],"Small Cell Lung Cancer",[311],{"trials":332,"activeCount":101},[],{"trials":334,"activeCount":101},[],{"trials":336,"activeCount":101},[],{"intervention":338,"totalTrials":97,"cells":339},"Osimertinib & febuxostat",{"EARLY_PHASE1":340,"PHASE1":342,"PHASE2":344,"PHASE3":357,"PHASE4":359,"NA":361},{"trials":341,"activeCount":101},[],{"trials":343,"activeCount":101},[],{"trials":345,"activeCount":97,"soonestReadout":350},[346],{"nctId":347,"briefTitle":348,"status":322,"phases":349,"primaryCompletion":350,"completion":351,"start":352,"enrollment":353,"conditions":354,"interventions":356},"NCT07485452","Boosting Osimertinib Blood Brain Barrier Penetration",[90],"2027-06","2028-06","2026-04",7,[355],"Non-Small Cell Lung Cancer",[338],{"trials":358,"activeCount":101},[],{"trials":360,"activeCount":101},[],{"trials":362,"activeCount":101},[],{"intervention":86,"totalTrials":97,"cells":364},{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":381,"PHASE4":383,"NA":385},{"trials":366,"activeCount":101},[],{"trials":368,"activeCount":101},[],{"trials":370,"activeCount":97,"soonestReadout":85},[371],{"nctId":83,"briefTitle":84,"status":113,"phases":372,"primaryCompletion":85,"completion":373,"start":374,"enrollment":375,"conditions":376,"interventions":378},[89,90],"2027-05","2023-05-30",126,[377],"Unspecified Adult Solid Tumor, Protocol Specific",[86,379,380],"Carboplatin","Immune checkpoint inhibitor",{"trials":382,"activeCount":101},[],{"trials":384,"activeCount":101},[],{"trials":386,"activeCount":101},[],{"intervention":379,"totalTrials":97,"cells":388},{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":393,"PHASE3":399,"PHASE4":401,"NA":403},{"trials":390,"activeCount":101},[],{"trials":392,"activeCount":101},[],{"trials":394,"activeCount":97,"soonestReadout":85},[395],{"nctId":83,"briefTitle":84,"status":113,"phases":396,"primaryCompletion":85,"completion":373,"start":374,"enrollment":375,"conditions":397,"interventions":398},[89,90],[377],[86,379,380],{"trials":400,"activeCount":101},[],{"trials":402,"activeCount":101},[],{"trials":404,"activeCount":101},[],{"intervention":380,"totalTrials":97,"cells":406},{"EARLY_PHASE1":407,"PHASE1":409,"PHASE2":411,"PHASE3":417,"PHASE4":419,"NA":421},{"trials":408,"activeCount":101},[],{"trials":410,"activeCount":101},[],{"trials":412,"activeCount":97,"soonestReadout":85},[413],{"nctId":83,"briefTitle":84,"status":113,"phases":414,"primaryCompletion":85,"completion":373,"start":374,"enrollment":375,"conditions":415,"interventions":416},[89,90],[377],[86,379,380],{"trials":418,"activeCount":101},[],{"trials":420,"activeCount":101},[],{"trials":422,"activeCount":101},[],{"intervention":52,"totalTrials":97,"cells":424},{"EARLY_PHASE1":425,"PHASE1":427,"PHASE2":429,"PHASE3":431,"PHASE4":433,"NA":435},{"trials":426,"activeCount":101},[],{"trials":428,"activeCount":101},[],{"trials":430,"activeCount":101},[],{"trials":432,"activeCount":101},[],{"trials":434,"activeCount":101},[],{"trials":436,"activeCount":97,"soonestReadout":51},[437],{"nctId":49,"briefTitle":50,"status":113,"phases":438,"primaryCompletion":51,"completion":51,"start":439,"enrollment":327,"conditions":440,"interventions":442},[93],"2024-05-03",[441],"Fibromyalgia",[52],{"intervention":81,"totalTrials":97,"cells":444},{"EARLY_PHASE1":445,"PHASE1":447,"PHASE2":449,"PHASE3":451,"PHASE4":453,"NA":455},{"trials":446,"activeCount":101},[],{"trials":448,"activeCount":101},[],{"trials":450,"activeCount":101},[],{"trials":452,"activeCount":101},[],{"trials":454,"activeCount":101},[],{"trials":456,"activeCount":97,"soonestReadout":80},[457],{"nctId":78,"briefTitle":79,"status":113,"phases":458,"primaryCompletion":80,"completion":80,"start":459,"enrollment":20,"conditions":460,"interventions":461},[93],"2025-06-01",[81],[81,462],"Knaster Hemp",{"intervention":462,"totalTrials":97,"cells":464},{"EARLY_PHASE1":465,"PHASE1":467,"PHASE2":469,"PHASE3":471,"PHASE4":473,"NA":475},{"trials":466,"activeCount":101},[],{"trials":468,"activeCount":101},[],{"trials":470,"activeCount":101},[],{"trials":472,"activeCount":101},[],{"trials":474,"activeCount":101},[],{"trials":476,"activeCount":97,"soonestReadout":80},[477],{"nctId":78,"briefTitle":79,"status":113,"phases":478,"primaryCompletion":80,"completion":80,"start":459,"enrollment":20,"conditions":479,"interventions":480},[93],[81],[81,462],{"intervention":482,"totalTrials":97,"cells":483},"Venous blood sampling prior to CCTA.",{"EARLY_PHASE1":484,"PHASE1":486,"PHASE2":488,"PHASE3":490,"PHASE4":492,"NA":494},{"trials":485,"activeCount":101},[],{"trials":487,"activeCount":101},[],{"trials":489,"activeCount":101},[],{"trials":491,"activeCount":101},[],{"trials":493,"activeCount":101},[],{"trials":495,"activeCount":97,"soonestReadout":500},[496],{"nctId":497,"briefTitle":498,"status":113,"phases":499,"primaryCompletion":500,"completion":500,"start":501,"enrollment":502,"conditions":503,"interventions":506},"NCT02381301","Biomarkers and Cardiac CT",[],"2029-12","2015-02",5000,[504,505],"Coronary Artery Disease","Atherosclerosis",[482],{"intervention":56,"totalTrials":97,"cells":508},{"EARLY_PHASE1":509,"PHASE1":511,"PHASE2":513,"PHASE3":515,"PHASE4":517,"NA":519},{"trials":510,"activeCount":101},[],{"trials":512,"activeCount":101},[],{"trials":514,"activeCount":101},[],{"trials":516,"activeCount":101},[],{"trials":518,"activeCount":101},[],{"trials":520,"activeCount":97,"soonestReadout":51},[521],{"nctId":54,"briefTitle":55,"status":113,"phases":522,"primaryCompletion":51,"completion":51,"start":523,"enrollment":524,"conditions":525,"interventions":527},[],"2016-03-01",40,[526],"Neoplasmata",[56],{"intervention":42,"totalTrials":97,"cells":529},{"EARLY_PHASE1":530,"PHASE1":532,"PHASE2":534,"PHASE3":536,"PHASE4":538,"NA":540},{"trials":531,"activeCount":101},[],{"trials":533,"activeCount":101},[],{"trials":535,"activeCount":101},[],{"trials":537,"activeCount":101},[],{"trials":539,"activeCount":101},[],{"trials":541,"activeCount":97,"soonestReadout":41},[542],{"nctId":39,"briefTitle":40,"status":113,"phases":543,"primaryCompletion":41,"completion":544,"start":545,"enrollment":546,"conditions":547,"interventions":549},[],"2035-01","2014-09",3600,[548],"Genetic Disease",[42],{"intervention":66,"totalTrials":97,"cells":551},{"EARLY_PHASE1":552,"PHASE1":554,"PHASE2":556,"PHASE3":558,"PHASE4":560,"NA":562},{"trials":553,"activeCount":101},[],{"trials":555,"activeCount":101},[],{"trials":557,"activeCount":101},[],{"trials":559,"activeCount":101},[],{"trials":561,"activeCount":101},[],{"trials":563,"activeCount":97,"soonestReadout":65},[564],{"nctId":63,"briefTitle":64,"status":113,"phases":565,"primaryCompletion":65,"completion":566,"start":567,"enrollment":568,"conditions":569,"interventions":581},[],"2026-12","2021-11-01",80,[570,571,572,573,574,575,576,577,578,579,580],"Basal Cell Carcinoma","Locally Advanced Basal Cell Carcinoma","Metastatic Basal Cell Carcinoma","Gorlin Syndrome","Basal Cell Nevus Syndrome","Carcinoma, Basal Cell","Carcinoma","Basal Cell Tumor","Skin Cancer","Neoplasm of Skin","Neoplasms, Basal Cell",[66,582],"Sonidegib",{"intervention":582,"totalTrials":97,"cells":584},{"EARLY_PHASE1":585,"PHASE1":587,"PHASE2":589,"PHASE3":591,"PHASE4":593,"NA":595},{"trials":586,"activeCount":101},[],{"trials":588,"activeCount":101},[],{"trials":590,"activeCount":101},[],{"trials":592,"activeCount":101},[],{"trials":594,"activeCount":101},[],{"trials":596,"activeCount":97,"soonestReadout":65},[597],{"nctId":63,"briefTitle":64,"status":113,"phases":598,"primaryCompletion":65,"completion":566,"start":567,"enrollment":568,"conditions":599,"interventions":600},[],[570,571,572,573,574,575,576,577,578,579,580],[66,582],{"intervention":602,"totalTrials":603,"cells":604},"Placebos",3,{"EARLY_PHASE1":605,"PHASE1":607,"PHASE2":609,"PHASE3":634,"PHASE4":636,"NA":648},{"trials":606,"activeCount":101},[],{"trials":608,"activeCount":101},[],{"trials":610,"activeCount":101},[611,624],{"nctId":612,"briefTitle":613,"status":614,"phases":615,"primaryCompletion":616,"completion":616,"start":617,"enrollment":618,"conditions":619,"interventions":622},"NCT03964688","Effect of Vitamin C in Autologous Stem Cell Transplantations","COMPLETED",[90],"2022-03-01","2019-12-10",47,[620,621],"Myeloma Multiple","Lymphoma",[623,602],"Vitamin C",{"nctId":625,"briefTitle":626,"status":614,"phases":627,"primaryCompletion":628,"completion":628,"start":629,"enrollment":630,"conditions":631,"interventions":632},"NCT03800290","Human Beta-2 Adrenergic Stimulation and Muscle Glucose Uptake",[90],"2021-04-23","2019-06-01",11,[19],[633,602],"Clenbuterol Hydrochloride",{"trials":635,"activeCount":101},[],{"trials":637,"activeCount":101},[638],{"nctId":639,"briefTitle":640,"status":614,"phases":641,"primaryCompletion":642,"completion":642,"start":643,"enrollment":10,"conditions":644,"interventions":646},"NCT03227900","Lidocaine and Food Intake",[92],"2018-06-26","2017-07-19",[645],"Hunger",[647,602],"Lidocaine",{"trials":649,"activeCount":101},[],{"intervention":651,"totalTrials":97,"cells":652},"240 mg Iodine",{"EARLY_PHASE1":653,"PHASE1":655,"PHASE2":657,"PHASE3":659,"PHASE4":661,"NA":676},{"trials":654,"activeCount":101},[],{"trials":656,"activeCount":101},[],{"trials":658,"activeCount":101},[],{"trials":660,"activeCount":101},[],{"trials":662,"activeCount":101},[663],{"nctId":664,"briefTitle":665,"status":614,"phases":666,"primaryCompletion":667,"completion":668,"start":669,"enrollment":670,"conditions":671,"interventions":673},"NCT02462044","Contrast Enhancement on Coronary Computed Tomographic Angiography",[92],"2015-08","2015-09","2014-08",200,[504,672],"Coronary Stenosis",[651,674,675],"300 mg Iodine","370 mg Iodine",{"trials":677,"activeCount":101},[],{"intervention":674,"totalTrials":97,"cells":679},{"EARLY_PHASE1":680,"PHASE1":682,"PHASE2":684,"PHASE3":686,"PHASE4":688,"NA":694},{"trials":681,"activeCount":101},[],{"trials":683,"activeCount":101},[],{"trials":685,"activeCount":101},[],{"trials":687,"activeCount":101},[],{"trials":689,"activeCount":101},[690],{"nctId":664,"briefTitle":665,"status":614,"phases":691,"primaryCompletion":667,"completion":668,"start":669,"enrollment":670,"conditions":692,"interventions":693},[92],[504,672],[651,674,675],{"trials":695,"activeCount":101},[],{"intervention":675,"totalTrials":97,"cells":697},{"EARLY_PHASE1":698,"PHASE1":700,"PHASE2":702,"PHASE3":704,"PHASE4":706,"NA":712},{"trials":699,"activeCount":101},[],{"trials":701,"activeCount":101},[],{"trials":703,"activeCount":101},[],{"trials":705,"activeCount":101},[],{"trials":707,"activeCount":101},[708],{"nctId":664,"briefTitle":665,"status":614,"phases":709,"primaryCompletion":667,"completion":668,"start":669,"enrollment":670,"conditions":710,"interventions":711},[92],[504,672],[651,674,675],{"trials":713,"activeCount":101},[],{"intervention":715,"totalTrials":97,"cells":716},"Euthyrox",{"EARLY_PHASE1":717,"PHASE1":719,"PHASE2":721,"PHASE3":723,"PHASE4":725,"NA":738},{"trials":718,"activeCount":101},[],{"trials":720,"activeCount":101},[],{"trials":722,"activeCount":101},[],{"trials":724,"activeCount":101},[],{"trials":726,"activeCount":101},[727],{"nctId":728,"briefTitle":729,"status":278,"phases":730,"primaryCompletion":731,"completion":731,"start":732,"enrollment":733,"conditions":734,"interventions":737},"NCT01379170","Thyroid Study Type 2 Diabetes Mellitus (T2DM)",[92],"2014-12","2011-06",17,[735,736],"Diabetes","Hypothyroidism",[715],{"trials":739,"activeCount":101},[],{"intervention":741,"totalTrials":97,"cells":742},"Eplerenone",{"EARLY_PHASE1":743,"PHASE1":745,"PHASE2":747,"PHASE3":749,"PHASE4":751,"NA":764},{"trials":744,"activeCount":101},[],{"trials":746,"activeCount":101},[],{"trials":748,"activeCount":101},[],{"trials":750,"activeCount":101},[],{"trials":752,"activeCount":101},[753],{"nctId":754,"briefTitle":755,"status":756,"phases":757,"primaryCompletion":758,"completion":758,"start":759,"enrollment":299,"conditions":760,"interventions":763},"NCT01887119","Aldosterone Antagonism and Microvascular Function","TERMINATED",[92],"2018-11","2013-10",[761,22,762],"Abdominal Obesity Metabolic Syndrome","Hypertension",[741],{"trials":765,"activeCount":101},[],{"intervention":767,"totalTrials":97,"cells":768},"Tiotropium 'Respimat' 5 mcg",{"EARLY_PHASE1":769,"PHASE1":771,"PHASE2":773,"PHASE3":775,"PHASE4":777,"NA":791},{"trials":770,"activeCount":101},[],{"trials":772,"activeCount":101},[],{"trials":774,"activeCount":101},[],{"trials":776,"activeCount":101},[],{"trials":778,"activeCount":101},[779],{"nctId":780,"briefTitle":781,"status":278,"phases":782,"primaryCompletion":783,"completion":784,"start":785,"enrollment":786,"conditions":787,"interventions":789},"NCT03275116","The Effect of Twice Daily vs. Once Daily Bronchodilation on Hyperinflation in COPD Patients During 24 Hours.",[92],"2020-04","2020-12","2017-07-07",49,[788],"Chronic Obstructive Airway Disease",[767,790],"Aclidinium Bromide\u002FFormoterol Fumarate 340\u002F12 mcg",{"trials":792,"activeCount":101},[],{"intervention":790,"totalTrials":97,"cells":794},{"EARLY_PHASE1":795,"PHASE1":797,"PHASE2":799,"PHASE3":801,"PHASE4":803,"NA":809},{"trials":796,"activeCount":101},[],{"trials":798,"activeCount":101},[],{"trials":800,"activeCount":101},[],{"trials":802,"activeCount":101},[],{"trials":804,"activeCount":101},[805],{"nctId":780,"briefTitle":781,"status":278,"phases":806,"primaryCompletion":783,"completion":784,"start":785,"enrollment":786,"conditions":807,"interventions":808},[92],[788],[767,790],{"trials":810,"activeCount":101},[],{"intervention":812,"totalTrials":97,"cells":813},"Fibrate treatment",{"EARLY_PHASE1":814,"PHASE1":816,"PHASE2":818,"PHASE3":820,"PHASE4":822,"NA":834},{"trials":815,"activeCount":101},[],{"trials":817,"activeCount":101},[],{"trials":819,"activeCount":101},[],{"trials":821,"activeCount":101},[],{"trials":823,"activeCount":101},[824],{"nctId":825,"briefTitle":826,"status":614,"phases":827,"primaryCompletion":828,"completion":828,"start":829,"enrollment":830,"conditions":831,"interventions":833},"NCT01527318","The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM)",[92],"2012-12","2011-08",6,[832],"Neutral Lipid Storage Disease",[812],{"trials":835,"activeCount":101},[],{"intervention":837,"totalTrials":97,"cells":838},"Oxycodone",{"EARLY_PHASE1":839,"PHASE1":841,"PHASE2":843,"PHASE3":845,"PHASE4":847,"NA":862},{"trials":840,"activeCount":101},[],{"trials":842,"activeCount":101},[],{"trials":844,"activeCount":101},[],{"trials":846,"activeCount":101},[],{"trials":848,"activeCount":101},[849],{"nctId":850,"briefTitle":851,"status":756,"phases":852,"primaryCompletion":853,"completion":853,"start":854,"enrollment":855,"conditions":856,"interventions":860},"NCT03616639","Neurotoxic Adverse Effects of Morphine and Oxycodone for Pain in Terminal Patients With Diminished Renal Function",[92],"2018-12-19","2018-06-04",8,[857,858,859],"Pain","Terminal Illness","Renal Impairment",[837,861],"Morphine",{"trials":863,"activeCount":101},[],{"intervention":861,"totalTrials":97,"cells":865},{"EARLY_PHASE1":866,"PHASE1":868,"PHASE2":870,"PHASE3":872,"PHASE4":874,"NA":880},{"trials":867,"activeCount":101},[],{"trials":869,"activeCount":101},[],{"trials":871,"activeCount":101},[],{"trials":873,"activeCount":101},[],{"trials":875,"activeCount":101},[876],{"nctId":850,"briefTitle":851,"status":756,"phases":877,"primaryCompletion":853,"completion":853,"start":854,"enrollment":855,"conditions":878,"interventions":879},[92],[857,858,859],[837,861],{"trials":881,"activeCount":101},[],{"intervention":883,"totalTrials":97,"cells":884},"5-fluorouracil",{"EARLY_PHASE1":885,"PHASE1":887,"PHASE2":889,"PHASE3":891,"PHASE4":893,"NA":908},{"trials":886,"activeCount":101},[],{"trials":888,"activeCount":101},[],{"trials":890,"activeCount":101},[],{"trials":892,"activeCount":101},[],{"trials":894,"activeCount":101},[895],{"nctId":896,"briefTitle":897,"status":278,"phases":898,"primaryCompletion":899,"completion":900,"start":901,"enrollment":902,"conditions":903,"interventions":905},"NCT02281682","IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis",[92],"2018-07","2018-12","2014-11",624,[904],"Keratosis, Actinic",[906,883,907],"Imiquimod","Ingenol mebutate",{"trials":909,"activeCount":101},[],{"intervention":907,"totalTrials":97,"cells":911},{"EARLY_PHASE1":912,"PHASE1":914,"PHASE2":916,"PHASE3":918,"PHASE4":920,"NA":926},{"trials":913,"activeCount":101},[],{"trials":915,"activeCount":101},[],{"trials":917,"activeCount":101},[],{"trials":919,"activeCount":101},[],{"trials":921,"activeCount":101},[922],{"nctId":896,"briefTitle":897,"status":278,"phases":923,"primaryCompletion":899,"completion":900,"start":901,"enrollment":902,"conditions":924,"interventions":925},[92],[904],[906,883,907],{"trials":927,"activeCount":101},[],{"intervention":929,"totalTrials":97,"cells":930},"Escitalopram",{"EARLY_PHASE1":931,"PHASE1":933,"PHASE2":935,"PHASE3":937,"PHASE4":939,"NA":952},{"trials":932,"activeCount":101},[],{"trials":934,"activeCount":101},[],{"trials":936,"activeCount":101},[],{"trials":938,"activeCount":101},[],{"trials":940,"activeCount":101},[941],{"nctId":942,"briefTitle":943,"status":614,"phases":944,"primaryCompletion":945,"completion":945,"start":946,"enrollment":947,"conditions":948,"interventions":951},"NCT01551225","Escitalopram Trial for Irritable Bowel Syndrome (IBS) Patients With Panic Disorder",[92],"2016-09","2012-01",32,[949,950],"Irritable Bowel Syndrome","Panic Disorder",[929],{"trials":953,"activeCount":101},[],{"intervention":955,"totalTrials":97,"cells":956},"Participants receive 10mg Empaglifozin once daily on prescription from their treating physician. This is not an intervention in this trial, but part of their normal HFpEF treatment",{"EARLY_PHASE1":957,"PHASE1":959,"PHASE2":961,"PHASE3":963,"PHASE4":965,"NA":979},{"trials":958,"activeCount":101},[],{"trials":960,"activeCount":101},[],{"trials":962,"activeCount":101},[],{"trials":964,"activeCount":101},[],{"trials":966,"activeCount":101},[967],{"nctId":968,"briefTitle":969,"status":278,"phases":970,"primaryCompletion":971,"completion":972,"start":973,"enrollment":974,"conditions":975,"interventions":978},"NCT06046612","Empagliflozin for Peripheral Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction",[92],"2024-08-13","2025-02-13","2023-02-13",48,[976,977],"Heart Failure With Preserved Ejection Fraction","Microvascular Dysfunction",[955],{"trials":980,"activeCount":101},[],{"intervention":982,"totalTrials":97,"cells":983},"Gadofosveset trisodium",{"EARLY_PHASE1":984,"PHASE1":986,"PHASE2":988,"PHASE3":990,"PHASE4":992,"NA":1002},{"trials":985,"activeCount":101},[],{"trials":987,"activeCount":101},[],{"trials":989,"activeCount":101},[],{"trials":991,"activeCount":101},[],{"trials":993,"activeCount":101},[994],{"nctId":995,"briefTitle":996,"status":997,"phases":998,"primaryCompletion":545,"completion":545,"start":545,"enrollment":101,"conditions":999,"interventions":1001},"NCT02243059","Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer","WITHDRAWN",[92],[1000],"Ovarian Neoplasms",[982],{"trials":1003,"activeCount":101},[],{"intervention":1005,"totalTrials":97,"cells":1006},"Methylphenidate",{"EARLY_PHASE1":1007,"PHASE1":1009,"PHASE2":1011,"PHASE3":1013,"PHASE4":1015,"NA":1025},{"trials":1008,"activeCount":101},[],{"trials":1010,"activeCount":101},[],{"trials":1012,"activeCount":101},[],{"trials":1014,"activeCount":101},[],{"trials":1016,"activeCount":101},[1017],{"nctId":1018,"briefTitle":1019,"status":278,"phases":1020,"primaryCompletion":1021,"completion":1021,"start":901,"enrollment":524,"conditions":1022,"interventions":1024},"NCT02326038","Ritalin, Memory and Attention in MCI: a Behaviour-EEG Study",[92],"2015-12",[1023],"Mild Cognitive Impairment",[1005],{"trials":1026,"activeCount":101},[],{"intervention":1028,"totalTrials":97,"cells":1029},"Liraglutide",{"EARLY_PHASE1":1030,"PHASE1":1032,"PHASE2":1034,"PHASE3":1036,"PHASE4":1038,"NA":1049},{"trials":1031,"activeCount":101},[],{"trials":1033,"activeCount":101},[],{"trials":1035,"activeCount":101},[],{"trials":1037,"activeCount":101},[],{"trials":1039,"activeCount":101},[1040],{"nctId":1041,"briefTitle":1042,"status":756,"phases":1043,"primaryCompletion":1044,"completion":1044,"start":1045,"enrollment":12,"conditions":1046,"interventions":1048},"NCT01638260","GLP-1 and Non-exercise Activity Thermogenesis in RHZ",[92],"2013-11","2012-10",[1047],"Type 2 Diabetes Mellitus",[1028],{"trials":1050,"activeCount":101},[],{"intervention":647,"totalTrials":97,"cells":1052},{"EARLY_PHASE1":1053,"PHASE1":1055,"PHASE2":1057,"PHASE3":1059,"PHASE4":1061,"NA":1067},{"trials":1054,"activeCount":101},[],{"trials":1056,"activeCount":101},[],{"trials":1058,"activeCount":101},[],{"trials":1060,"activeCount":101},[],{"trials":1062,"activeCount":101},[1063],{"nctId":639,"briefTitle":640,"status":614,"phases":1064,"primaryCompletion":642,"completion":642,"start":643,"enrollment":10,"conditions":1065,"interventions":1066},[92],[645],[647,602],{"trials":1068,"activeCount":101},[],{"intervention":1070,"totalTrials":97,"cells":1071},"fentanyl",{"EARLY_PHASE1":1072,"PHASE1":1074,"PHASE2":1076,"PHASE3":1078,"PHASE4":1080,"NA":1093},{"trials":1073,"activeCount":101},[],{"trials":1075,"activeCount":101},[],{"trials":1077,"activeCount":101},[],{"trials":1079,"activeCount":101},[],{"trials":1081,"activeCount":101},[1082],{"nctId":1083,"briefTitle":1084,"status":614,"phases":1085,"primaryCompletion":1086,"completion":1086,"start":1087,"enrollment":1088,"conditions":1089,"interventions":1091},"NCT01317589","Treatment of Pain in Head-and-Neck Cancer Patients: is Methadone More Effective?",[92],"2015-07","2011-05",134,[857,1090],"Cancer of Head and Neck",[1070,1092],"methadone",{"trials":1094,"activeCount":101},[],{"intervention":1092,"totalTrials":97,"cells":1096},{"EARLY_PHASE1":1097,"PHASE1":1099,"PHASE2":1101,"PHASE3":1103,"PHASE4":1105,"NA":1111},{"trials":1098,"activeCount":101},[],{"trials":1100,"activeCount":101},[],{"trials":1102,"activeCount":101},[],{"trials":1104,"activeCount":101},[],{"trials":1106,"activeCount":101},[1107],{"nctId":1083,"briefTitle":1084,"status":614,"phases":1108,"primaryCompletion":1086,"completion":1086,"start":1087,"enrollment":1088,"conditions":1109,"interventions":1110},[92],[857,1090],[1070,1092],{"trials":1112,"activeCount":101},[],{"intervention":1114,"totalTrials":97,"cells":1115},"Vernakalant",{"EARLY_PHASE1":1116,"PHASE1":1118,"PHASE2":1120,"PHASE3":1122,"PHASE4":1124,"NA":1136},{"trials":1117,"activeCount":101},[],{"trials":1119,"activeCount":101},[],{"trials":1121,"activeCount":101},[],{"trials":1123,"activeCount":101},[],{"trials":1125,"activeCount":101},[1126],{"nctId":1127,"briefTitle":1128,"status":278,"phases":1129,"primaryCompletion":1130,"completion":1130,"start":1131,"enrollment":1132,"conditions":1133,"interventions":1134},"NCT01646281","Vernakalant Versus Flecainide: Atrial Contractility",[92],"2013-08","2012-08",70,[30],[1114,1135],"Flecainide",{"trials":1137,"activeCount":101},[],{"intervention":1135,"totalTrials":97,"cells":1139},{"EARLY_PHASE1":1140,"PHASE1":1142,"PHASE2":1144,"PHASE3":1146,"PHASE4":1148,"NA":1154},{"trials":1141,"activeCount":101},[],{"trials":1143,"activeCount":101},[],{"trials":1145,"activeCount":101},[],{"trials":1147,"activeCount":101},[],{"trials":1149,"activeCount":101},[1150],{"nctId":1127,"briefTitle":1128,"status":278,"phases":1151,"primaryCompletion":1130,"completion":1130,"start":1131,"enrollment":1132,"conditions":1152,"interventions":1153},[92],[30],[1114,1135],{"trials":1155,"activeCount":101},[],{"intervention":1157,"totalTrials":97,"cells":1158},"sustained release morphine",{"EARLY_PHASE1":1159,"PHASE1":1161,"PHASE2":1163,"PHASE3":1165,"PHASE4":1167,"NA":1180},{"trials":1160,"activeCount":101},[],{"trials":1162,"activeCount":101},[],{"trials":1164,"activeCount":101},[],{"trials":1166,"activeCount":101},[],{"trials":1168,"activeCount":101},[1169],{"nctId":1170,"briefTitle":1171,"status":614,"phases":1172,"primaryCompletion":1173,"completion":1174,"start":1175,"enrollment":1176,"conditions":1177,"interventions":1179},"NCT02429050","Morphine for Treatment of Dyspnea in Patients With COPD",[92],"2019-03-06","2019-07-01","2016-11-16",124,[1178],"Pulmonary Disease, Chronic Obstructive",[1157],{"trials":1181,"activeCount":101},[],{"intervention":1183,"totalTrials":97,"cells":1184},"Ferinject",{"EARLY_PHASE1":1185,"PHASE1":1187,"PHASE2":1189,"PHASE3":1191,"PHASE4":1193,"NA":1207},{"trials":1186,"activeCount":101},[],{"trials":1188,"activeCount":101},[],{"trials":1190,"activeCount":101},[],{"trials":1192,"activeCount":101},[],{"trials":1194,"activeCount":101},[1195],{"nctId":1196,"briefTitle":1197,"status":756,"phases":1198,"primaryCompletion":1199,"completion":1200,"start":1201,"enrollment":1202,"conditions":1203,"interventions":1205},"NCT01975272","The Use of Iron Therapy for Patients With Anemia After Caesarean Section",[92],"2018-05-17","2018-06-21","2015-03-02",27,[1204],"Postoperative Anaemia",[1183,1206],"Ferrous fumarate",{"trials":1208,"activeCount":101},[],{"intervention":1206,"totalTrials":97,"cells":1210},{"EARLY_PHASE1":1211,"PHASE1":1213,"PHASE2":1215,"PHASE3":1217,"PHASE4":1219,"NA":1225},{"trials":1212,"activeCount":101},[],{"trials":1214,"activeCount":101},[],{"trials":1216,"activeCount":101},[],{"trials":1218,"activeCount":101},[],{"trials":1220,"activeCount":101},[1221],{"nctId":1196,"briefTitle":1197,"status":756,"phases":1222,"primaryCompletion":1199,"completion":1200,"start":1201,"enrollment":1202,"conditions":1223,"interventions":1224},[92],[1204],[1183,1206],{"trials":1226,"activeCount":101},[],{"intervention":1228,"totalTrials":97,"cells":1229},"Movicol",{"EARLY_PHASE1":1230,"PHASE1":1232,"PHASE2":1234,"PHASE3":1236,"PHASE4":1238,"NA":1249},{"trials":1231,"activeCount":101},[],{"trials":1233,"activeCount":101},[],{"trials":1235,"activeCount":101},[],{"trials":1237,"activeCount":101},[],{"trials":1239,"activeCount":101},[1240],{"nctId":1241,"briefTitle":1242,"status":278,"phases":1243,"primaryCompletion":1244,"start":1245,"enrollment":568,"conditions":1246,"interventions":1248},"NCT01429779","The Orange-III Trial: Optimised Recovery With Movicol® Preoperatively Within an Enhanced Recovery Programme",[92],"2014-10","2012-07",[1247],"Liver Diseases",[1228],{"trials":1250,"activeCount":101},[],{"intervention":1252,"totalTrials":97,"cells":1253},"PCM\u002FOxy1",{"EARLY_PHASE1":1254,"PHASE1":1256,"PHASE2":1258,"PHASE3":1260,"PHASE4":1262,"NA":1275},{"trials":1255,"activeCount":101},[],{"trials":1257,"activeCount":101},[],{"trials":1259,"activeCount":101},[],{"trials":1261,"activeCount":101},[],{"trials":1263,"activeCount":101},[1264],{"nctId":1265,"briefTitle":1266,"status":614,"phases":1267,"primaryCompletion":1268,"start":1269,"enrollment":1270,"conditions":1271,"interventions":1273},"NCT02152592","Controlled-Release Oxycodone Versus Naproxen at Home After Ambulatory Surgery: A Randomized Controlled Trial",[92],"2009-03","2007-10",105,[1272],"Postoperative Pain After Ambulatory Surgery",[1252,1274],"PCM\u002FOxy2",{"trials":1276,"activeCount":101},[],{"intervention":1274,"totalTrials":97,"cells":1278},{"EARLY_PHASE1":1279,"PHASE1":1281,"PHASE2":1283,"PHASE3":1285,"PHASE4":1287,"NA":1293},{"trials":1280,"activeCount":101},[],{"trials":1282,"activeCount":101},[],{"trials":1284,"activeCount":101},[],{"trials":1286,"activeCount":101},[],{"trials":1288,"activeCount":101},[1289],{"nctId":1265,"briefTitle":1266,"status":614,"phases":1290,"primaryCompletion":1268,"start":1269,"enrollment":1270,"conditions":1291,"interventions":1292},[92],[1272],[1252,1274],{"trials":1294,"activeCount":101},[],{"intervention":1296,"totalTrials":97,"cells":1297},"Methyl Aminolevulinate (Mal) for Topical Administration, 16.8%, 1 Gram",{"EARLY_PHASE1":1298,"PHASE1":1300,"PHASE2":1302,"PHASE3":1304,"PHASE4":1306,"NA":1320},{"trials":1299,"activeCount":101},[],{"trials":1301,"activeCount":101},[],{"trials":1303,"activeCount":101},[],{"trials":1305,"activeCount":101},[],{"trials":1307,"activeCount":101},[1308],{"nctId":1309,"briefTitle":1310,"status":614,"phases":1311,"primaryCompletion":1312,"completion":1313,"start":1314,"enrollment":1315,"conditions":1316,"interventions":1318},"NCT03909646","Surgical Excision Versus Photodynamic Therapy and Topical 5-fluorouracil in Treatment of Bowen's Disease",[92],"2022-03-02","2024-12-12","2019-05-27",250,[1317],"Bowen's Disease",[1296,1319],"5Fluorouracil",{"trials":1321,"activeCount":101},[],{"intervention":1319,"totalTrials":97,"cells":1323},{"EARLY_PHASE1":1324,"PHASE1":1326,"PHASE2":1328,"PHASE3":1330,"PHASE4":1332,"NA":1338},{"trials":1325,"activeCount":101},[],{"trials":1327,"activeCount":101},[],{"trials":1329,"activeCount":101},[],{"trials":1331,"activeCount":101},[],{"trials":1333,"activeCount":101},[1334],{"nctId":1309,"briefTitle":1310,"status":614,"phases":1335,"primaryCompletion":1312,"completion":1313,"start":1314,"enrollment":1315,"conditions":1336,"interventions":1337},[92],[1317],[1296,1319],{"trials":1339,"activeCount":101},[],{"intervention":1341,"totalTrials":97,"cells":1342},"Methylaminolevulinate PDT in 2 sessions",{"EARLY_PHASE1":1343,"PHASE1":1345,"PHASE2":1347,"PHASE3":1349,"PHASE4":1351,"NA":1363},{"trials":1344,"activeCount":101},[],{"trials":1346,"activeCount":101},[],{"trials":1348,"activeCount":101},[],{"trials":1350,"activeCount":101},[],{"trials":1352,"activeCount":101},[1353],{"nctId":1354,"briefTitle":1355,"status":278,"phases":1356,"primaryCompletion":1357,"completion":1357,"start":1130,"enrollment":1358,"conditions":1359,"interventions":1361},"NCT01491711","Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate",[92],"2015-04",162,[1360],"Superficial Basal Cell Carcinoma",[1341,1362],"Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT",{"trials":1364,"activeCount":101},[],{"intervention":1362,"totalTrials":97,"cells":1366},{"EARLY_PHASE1":1367,"PHASE1":1369,"PHASE2":1371,"PHASE3":1373,"PHASE4":1375,"NA":1381},{"trials":1368,"activeCount":101},[],{"trials":1370,"activeCount":101},[],{"trials":1372,"activeCount":101},[],{"trials":1374,"activeCount":101},[],{"trials":1376,"activeCount":101},[1377],{"nctId":1354,"briefTitle":1355,"status":278,"phases":1378,"primaryCompletion":1357,"completion":1357,"start":1130,"enrollment":1358,"conditions":1379,"interventions":1380},[92],[1360],[1341,1362],{"trials":1382,"activeCount":101},[],{"intervention":1384,"totalTrials":97,"cells":1385},"4.8 g\u002Fm^2\u002Fday NaPB",{"EARLY_PHASE1":1386,"PHASE1":1388,"PHASE2":1390,"PHASE3":1392,"PHASE4":1394,"NA":1407},{"trials":1387,"activeCount":101},[],{"trials":1389,"activeCount":101},[],{"trials":1391,"activeCount":101},[],{"trials":1393,"activeCount":101},[],{"trials":1395,"activeCount":101},[1396],{"nctId":1397,"briefTitle":1398,"status":278,"phases":1399,"primaryCompletion":1400,"completion":326,"start":1401,"enrollment":1402,"conditions":1403,"interventions":1405},"NCT05836350","Role of BCAA in Glucose Homeostasis",[92],"2025-10","2023-06",20,[1404],"Type 2 Diabetes",[1384,1406],"4.8 g\u002Fm^2\u002Fday placebo",{"trials":1408,"activeCount":101},[],{"intervention":1406,"totalTrials":97,"cells":1410},{"EARLY_PHASE1":1411,"PHASE1":1413,"PHASE2":1415,"PHASE3":1417,"PHASE4":1419,"NA":1425},{"trials":1412,"activeCount":101},[],{"trials":1414,"activeCount":101},[],{"trials":1416,"activeCount":101},[],{"trials":1418,"activeCount":101},[],{"trials":1420,"activeCount":101},[1421],{"nctId":1397,"briefTitle":1398,"status":278,"phases":1422,"primaryCompletion":1400,"completion":326,"start":1401,"enrollment":1402,"conditions":1423,"interventions":1424},[92],[1404],[1384,1406],{"trials":1426,"activeCount":101},[],{"intervention":1428,"totalTrials":97,"cells":1429},"sertraline",{"EARLY_PHASE1":1430,"PHASE1":1432,"PHASE2":1434,"PHASE3":1436,"PHASE4":1438,"NA":1452},{"trials":1431,"activeCount":101},[],{"trials":1433,"activeCount":101},[],{"trials":1435,"activeCount":101},[],{"trials":1437,"activeCount":101},[],{"trials":1439,"activeCount":101},[1440],{"nctId":1441,"briefTitle":1442,"status":614,"phases":1443,"primaryCompletion":1444,"completion":1444,"start":1445,"enrollment":1446,"conditions":1447,"interventions":1451},"NCT01114100","The Effects of Treatment With Sertraline for Noncardiac Chest Pain",[92],"2002-12","2000-01",210,[1448,1449,1450],"Panic Attacks","Chest Pain","Depression",[1428],{"trials":1453,"activeCount":101},[],{"intervention":1455,"totalTrials":97,"cells":1456},"Labetalol",{"EARLY_PHASE1":1457,"PHASE1":1459,"PHASE2":1461,"PHASE3":1463,"PHASE4":1465,"NA":1481},{"trials":1458,"activeCount":101},[],{"trials":1460,"activeCount":101},[],{"trials":1462,"activeCount":101},[],{"trials":1464,"activeCount":101},[],{"trials":1466,"activeCount":101},[1467],{"nctId":1468,"briefTitle":1469,"status":278,"phases":1470,"primaryCompletion":1471,"completion":1472,"start":1473,"enrollment":1474,"conditions":1475,"interventions":1478},"NCT02531490","Early Vascular Adjustments During Hypertensive Pregnancy",[92],"2023-02","2023-04","2015-01-01",368,[1476,1477],"Hypertension, Pregnancy-Induced","Pre-Eclampsia",[1455,1479,1480],"Nifedipine","Methyldopa",{"trials":1482,"activeCount":101},[],{"intervention":1479,"totalTrials":97,"cells":1484},{"EARLY_PHASE1":1485,"PHASE1":1487,"PHASE2":1489,"PHASE3":1491,"PHASE4":1493,"NA":1499},{"trials":1486,"activeCount":101},[],{"trials":1488,"activeCount":101},[],{"trials":1490,"activeCount":101},[],{"trials":1492,"activeCount":101},[],{"trials":1494,"activeCount":101},[1495],{"nctId":1468,"briefTitle":1469,"status":278,"phases":1496,"primaryCompletion":1471,"completion":1472,"start":1473,"enrollment":1474,"conditions":1497,"interventions":1498},[92],[1476,1477],[1455,1479,1480],{"trials":1500,"activeCount":101},[],{"intervention":1480,"totalTrials":97,"cells":1502},{"EARLY_PHASE1":1503,"PHASE1":1505,"PHASE2":1507,"PHASE3":1509,"PHASE4":1511,"NA":1517},{"trials":1504,"activeCount":101},[],{"trials":1506,"activeCount":101},[],{"trials":1508,"activeCount":101},[],{"trials":1510,"activeCount":101},[],{"trials":1512,"activeCount":101},[1513],{"nctId":1468,"briefTitle":1469,"status":278,"phases":1514,"primaryCompletion":1471,"completion":1472,"start":1473,"enrollment":1474,"conditions":1515,"interventions":1516},[92],[1476,1477],[1455,1479,1480],{"trials":1518,"activeCount":101},[],{"intervention":1520,"totalTrials":97,"cells":1521},"Dapagliflozin 10mg",{"EARLY_PHASE1":1522,"PHASE1":1524,"PHASE2":1526,"PHASE3":1528,"PHASE4":1530,"NA":1542},{"trials":1523,"activeCount":101},[],{"trials":1525,"activeCount":101},[],{"trials":1527,"activeCount":101},[],{"trials":1529,"activeCount":101},[],{"trials":1531,"activeCount":101},[1532],{"nctId":1533,"briefTitle":1534,"status":614,"phases":1535,"primaryCompletion":1536,"completion":1536,"start":1537,"enrollment":31,"conditions":1538,"interventions":1541},"NCT03721874","Effects of 2 Weeks Treatment With Dapagliflozin in Subjects With an Impaired Glucose Homeostasis on Nocturnal Substrate Oxidation",[92],"2021-06-29","2019-04-30",[1539,1540],"Prediabetic State","Substrate Oxidation",[1520],{"trials":1543,"activeCount":101},[],{"intervention":1545,"totalTrials":97,"cells":1546},"Ribavirin",{"EARLY_PHASE1":1547,"PHASE1":1549,"PHASE2":1551,"PHASE3":1553,"PHASE4":1555,"NA":1565},{"trials":1548,"activeCount":101},[],{"trials":1550,"activeCount":101},[],{"trials":1552,"activeCount":101},[],{"trials":1554,"activeCount":101},[],{"trials":1556,"activeCount":101},[1557],{"nctId":1558,"briefTitle":1559,"status":614,"phases":1560,"primaryCompletion":828,"completion":828,"start":1561,"enrollment":34,"conditions":1562,"interventions":1564},"NCT00484328","Ribavirin, Its Dosing Regime",[92],"2007-07",[1563],"Hepatitis C",[1545],{"trials":1566,"activeCount":101},[],{"intervention":1568,"totalTrials":97,"cells":1569},"Ciprofibrate 100Mg",{"EARLY_PHASE1":1570,"PHASE1":1572,"PHASE2":1574,"PHASE3":1576,"PHASE4":1590,"NA":1592},{"trials":1571,"activeCount":101},[],{"trials":1573,"activeCount":101},[],{"trials":1575,"activeCount":101},[],{"trials":1577,"activeCount":101},[1578],{"nctId":1579,"briefTitle":1580,"status":614,"phases":1581,"primaryCompletion":1582,"completion":1583,"start":1584,"enrollment":630,"conditions":1585,"interventions":1589},"NCT03662984","Ciprofibrate and Pre-diabetes",[91],"2020-11-06","2020-11-13","2018-11-01",[1586,1587,1588],"Myocardial Insulin Sensitivity","Impaired Glucose Metabolism","Diastolic Dysfunction",[1568],{"trials":1591,"activeCount":101},[],{"trials":1593,"activeCount":101},[],{"intervention":1595,"totalTrials":97,"cells":1596},"Hydroxyethylrutoside",{"EARLY_PHASE1":1597,"PHASE1":1599,"PHASE2":1601,"PHASE3":1603,"PHASE4":1615,"NA":1617},{"trials":1598,"activeCount":101},[],{"trials":1600,"activeCount":101},[],{"trials":1602,"activeCount":101},[],{"trials":1604,"activeCount":101},[1605],{"nctId":1606,"briefTitle":1607,"status":614,"phases":1608,"primaryCompletion":1609,"completion":1609,"start":1610,"enrollment":1611,"conditions":1612,"interventions":1614},"NCT04670432","Resolution Enhancement by a Supplemental Obstruction Lessening Venoactive Drug for Eight Weeks in Deep Vein Thrombosis",[91],"2023-11-28","2020-12-08",44,[1613],"Deep Vein Thrombosis",[1595],{"trials":1616,"activeCount":101},[],{"trials":1618,"activeCount":101},[],{"intervention":1620,"totalTrials":97,"cells":1621},"L-arginine",{"EARLY_PHASE1":1622,"PHASE1":1624,"PHASE2":1626,"PHASE3":1628,"PHASE4":1640,"NA":1642},{"trials":1623,"activeCount":101},[],{"trials":1625,"activeCount":101},[],{"trials":1627,"activeCount":101},[],{"trials":1629,"activeCount":101},[1630],{"nctId":1631,"briefTitle":1632,"status":278,"phases":1633,"primaryCompletion":1634,"completion":1021,"start":901,"enrollment":10,"conditions":1635,"interventions":1639},"NCT02291458","L-arginine and Brown Adipose Tissue",[91],"2015-10",[1636,1637,1638],"Adipose Tissue, Brown","Glucose Intolerance","Nitric Oxide",[1620],{"trials":1641,"activeCount":101},[],{"trials":1643,"activeCount":101},[],{"intervention":1645,"totalTrials":97,"cells":1646},"Pilocarpine",{"EARLY_PHASE1":1647,"PHASE1":1649,"PHASE2":1651,"PHASE3":1653,"PHASE4":1667,"NA":1669},{"trials":1648,"activeCount":101},[],{"trials":1650,"activeCount":101},[],{"trials":1652,"activeCount":101},[],{"trials":1654,"activeCount":101},[1655],{"nctId":1656,"briefTitle":1657,"status":278,"phases":1658,"primaryCompletion":1659,"completion":1660,"start":1661,"enrollment":1662,"conditions":1663,"interventions":1666},"NCT05506137","Xerostomia in Patients With a Life-limiting Condition or Frailty",[91],"2025-02","2025-06","2023-01",120,[1664,1665],"Xerostomia","Dry Mouth",[1645],{"trials":1668,"activeCount":101},[],{"trials":1670,"activeCount":101},[],{"intervention":1672,"totalTrials":97,"cells":1673},"18F-Flutemetamol PET\u002FMRI",{"EARLY_PHASE1":1674,"PHASE1":1676,"PHASE2":1678,"PHASE3":1680,"PHASE4":1690,"NA":1692},{"trials":1675,"activeCount":101},[],{"trials":1677,"activeCount":101},[],{"trials":1679,"activeCount":101},[],{"trials":1681,"activeCount":101},[1682],{"nctId":1683,"briefTitle":1684,"status":278,"phases":1685,"primaryCompletion":1686,"completion":1686,"start":1687,"enrollment":299,"conditions":1688,"interventions":1689},"NCT03291093","18F-Flutemetamol and Plaque Vulnerability",[90,91],"2019-12-31","2018-02-01",[505],[1672],{"trials":1691,"activeCount":101},[],{"trials":1693,"activeCount":101},[],{"intervention":1695,"totalTrials":97,"cells":1696},"18F-choline PET-MR imaging",{"EARLY_PHASE1":1697,"PHASE1":1699,"PHASE2":1701,"PHASE3":1703,"PHASE4":1713,"NA":1715},{"trials":1698,"activeCount":101},[],{"trials":1700,"activeCount":101},[],{"trials":1702,"activeCount":101},[],{"trials":1704,"activeCount":101},[1705],{"nctId":1706,"briefTitle":1707,"status":278,"phases":1708,"primaryCompletion":280,"completion":280,"start":1021,"enrollment":1709,"conditions":1710,"interventions":1712},"NCT02640313","Molecular Imaging of Plaque Vulnerability",[91],14,[1711],"Plaque, Atherosclerotic",[1695],{"trials":1714,"activeCount":101},[],{"trials":1716,"activeCount":101},[],{"intervention":1718,"totalTrials":97,"cells":1719},"Imiquimod 5% cream with prior curettage",{"EARLY_PHASE1":1720,"PHASE1":1722,"PHASE2":1724,"PHASE3":1726,"PHASE4":1739,"NA":1741},{"trials":1721,"activeCount":101},[],{"trials":1723,"activeCount":101},[],{"trials":1725,"activeCount":101},[],{"trials":1727,"activeCount":101},[1728],{"nctId":1729,"briefTitle":1730,"status":278,"phases":1731,"primaryCompletion":1732,"completion":1733,"start":1734,"enrollment":1735,"conditions":1736,"interventions":1738},"NCT02242929","Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma",[91],"2017-12","2022-12","2016-01",145,[1737],"Nodular Basal Cell Carcinoma",[1718],{"trials":1740,"activeCount":101},[],{"trials":1742,"activeCount":101},[],{"intervention":1744,"totalTrials":97,"cells":1745},"Adenosine 5'-triphosphate",{"EARLY_PHASE1":1746,"PHASE1":1748,"PHASE2":1750,"PHASE3":1752,"PHASE4":1767,"NA":1769},{"trials":1747,"activeCount":101},[],{"trials":1749,"activeCount":101},[],{"trials":1751,"activeCount":101},[],{"trials":1753,"activeCount":101},[1754],{"nctId":1755,"briefTitle":1756,"status":614,"phases":1757,"completion":1758,"start":1759,"enrollment":1760,"conditions":1761,"interventions":1766},"NCT00565188","Application of ATP Infusions in Palliative Home Care",[91],"2006-10","2002-03",100,[1762,1763,1764,1765],"Cancer","Palliative Care","Survival","Quality of Life",[1744],{"trials":1768,"activeCount":101},[],{"trials":1770,"activeCount":101},[],{"intervention":1772,"totalTrials":97,"cells":1773},"Bromfenac",{"EARLY_PHASE1":1774,"PHASE1":1776,"PHASE2":1778,"PHASE3":1780,"PHASE4":1797,"NA":1799},{"trials":1775,"activeCount":101},[],{"trials":1777,"activeCount":101},[],{"trials":1779,"activeCount":101},[],{"trials":1781,"activeCount":101},[1782],{"nctId":1783,"briefTitle":1784,"status":614,"phases":1785,"primaryCompletion":1786,"completion":1786,"start":1787,"enrollment":1788,"conditions":1789,"interventions":1793},"NCT01774474","PRevention of Macular EDema After Cataract Surgery",[91],"2016-11-04","2013-07-10",1127,[1790,1791,1792],"Cystoid Macular Edema","Cataract","Diabetes Mellitus",[1772,1794,1795,1796],"Dexamethasone","Bevacizumab","Triamcinolone Acetonide",{"trials":1798,"activeCount":101},[],{"trials":1800,"activeCount":101},[],{"intervention":1794,"totalTrials":97,"cells":1802},{"EARLY_PHASE1":1803,"PHASE1":1805,"PHASE2":1807,"PHASE3":1809,"PHASE4":1815,"NA":1817},{"trials":1804,"activeCount":101},[],{"trials":1806,"activeCount":101},[],{"trials":1808,"activeCount":101},[],{"trials":1810,"activeCount":101},[1811],{"nctId":1783,"briefTitle":1784,"status":614,"phases":1812,"primaryCompletion":1786,"completion":1786,"start":1787,"enrollment":1788,"conditions":1813,"interventions":1814},[91],[1790,1791,1792],[1772,1794,1795,1796],{"trials":1816,"activeCount":101},[],{"trials":1818,"activeCount":101},[],{"intervention":1795,"totalTrials":97,"cells":1820},{"EARLY_PHASE1":1821,"PHASE1":1823,"PHASE2":1825,"PHASE3":1827,"PHASE4":1833,"NA":1835},{"trials":1822,"activeCount":101},[],{"trials":1824,"activeCount":101},[],{"trials":1826,"activeCount":101},[],{"trials":1828,"activeCount":101},[1829],{"nctId":1783,"briefTitle":1784,"status":614,"phases":1830,"primaryCompletion":1786,"completion":1786,"start":1787,"enrollment":1788,"conditions":1831,"interventions":1832},[91],[1790,1791,1792],[1772,1794,1795,1796],{"trials":1834,"activeCount":101},[],{"trials":1836,"activeCount":101},[],{"intervention":1796,"totalTrials":97,"cells":1838},{"EARLY_PHASE1":1839,"PHASE1":1841,"PHASE2":1843,"PHASE3":1845,"PHASE4":1851,"NA":1853},{"trials":1840,"activeCount":101},[],{"trials":1842,"activeCount":101},[],{"trials":1844,"activeCount":101},[],{"trials":1846,"activeCount":101},[1847],{"nctId":1783,"briefTitle":1784,"status":614,"phases":1848,"primaryCompletion":1786,"completion":1786,"start":1787,"enrollment":1788,"conditions":1849,"interventions":1850},[91],[1790,1791,1792],[1772,1794,1795,1796],{"trials":1852,"activeCount":101},[],{"trials":1854,"activeCount":101},[],{"intervention":1856,"totalTrials":97,"cells":1857},"Anastrozole",{"EARLY_PHASE1":1858,"PHASE1":1860,"PHASE2":1862,"PHASE3":1864,"PHASE4":1875,"NA":1877},{"trials":1859,"activeCount":101},[],{"trials":1861,"activeCount":101},[],{"trials":1863,"activeCount":101},[],{"trials":1865,"activeCount":101},[1866],{"nctId":1867,"briefTitle":1868,"status":614,"phases":1869,"primaryCompletion":1870,"completion":1870,"start":1871,"enrollment":1872,"conditions":1873,"interventions":1874},"NCT00301457","Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer",[91],"2022-04","2006-06",1914,[27],[1856],{"trials":1876,"activeCount":101},[],{"trials":1878,"activeCount":101},[],{"intervention":1880,"totalTrials":97,"cells":1881},"baclofen, intrathecal",{"EARLY_PHASE1":1882,"PHASE1":1884,"PHASE2":1886,"PHASE3":1888,"PHASE4":1900,"NA":1902},{"trials":1883,"activeCount":101},[],{"trials":1885,"activeCount":101},[],{"trials":1887,"activeCount":101},[],{"trials":1889,"activeCount":101},[1890],{"nctId":1891,"briefTitle":1892,"status":614,"phases":1893,"completion":1894,"start":1895,"enrollment":28,"conditions":1896,"interventions":1899},"NCT00367068","Dutch National ITB Study in Children With Cerebral Palsy",[91],"2007-05","2002-01",[1897,1898],"Cerebral Palsy","Spasticity",[1880],{"trials":1901,"activeCount":101},[],{"trials":1903,"activeCount":101},[],{"intervention":1905,"totalTrials":97,"cells":1906},"standard anaesthesia",{"EARLY_PHASE1":1907,"PHASE1":1909,"PHASE2":1911,"PHASE3":1913,"PHASE4":1925,"NA":1927},{"trials":1908,"activeCount":101},[],{"trials":1910,"activeCount":101},[],{"trials":1912,"activeCount":101},[],{"trials":1914,"activeCount":101},[1915],{"nctId":1916,"briefTitle":1917,"status":614,"phases":1918,"primaryCompletion":1919,"completion":1087,"start":1758,"enrollment":1920,"conditions":1921,"interventions":1922},"NCT00547989","Paravertebral Block, an Adjunct to General Anaesthesia for Breast Surgery?",[91],"2010-12",46,[27],[1905,1923,1924],"additional pvb (ropivacaine) and elastomeric disposable infusion pump","additional pvb",{"trials":1926,"activeCount":101},[],{"trials":1928,"activeCount":101},[],{"intervention":1923,"totalTrials":97,"cells":1930},{"EARLY_PHASE1":1931,"PHASE1":1933,"PHASE2":1935,"PHASE3":1937,"PHASE4":1943,"NA":1945},{"trials":1932,"activeCount":101},[],{"trials":1934,"activeCount":101},[],{"trials":1936,"activeCount":101},[],{"trials":1938,"activeCount":101},[1939],{"nctId":1916,"briefTitle":1917,"status":614,"phases":1940,"primaryCompletion":1919,"completion":1087,"start":1758,"enrollment":1920,"conditions":1941,"interventions":1942},[91],[27],[1905,1923,1924],{"trials":1944,"activeCount":101},[],{"trials":1946,"activeCount":101},[],{"intervention":1924,"totalTrials":97,"cells":1948},{"EARLY_PHASE1":1949,"PHASE1":1951,"PHASE2":1953,"PHASE3":1955,"PHASE4":1961,"NA":1963},{"trials":1950,"activeCount":101},[],{"trials":1952,"activeCount":101},[],{"trials":1954,"activeCount":101},[],{"trials":1956,"activeCount":101},[1957],{"nctId":1916,"briefTitle":1917,"status":614,"phases":1958,"primaryCompletion":1919,"completion":1087,"start":1758,"enrollment":1920,"conditions":1959,"interventions":1960},[91],[27],[1905,1923,1924],{"trials":1962,"activeCount":101},[],{"trials":1964,"activeCount":101},[],{"intervention":1966,"totalTrials":97,"cells":1967},"Rapamycin",{"EARLY_PHASE1":1968,"PHASE1":1970,"PHASE2":1972,"PHASE3":1974,"PHASE4":1985,"NA":1987},{"trials":1969,"activeCount":101},[],{"trials":1971,"activeCount":101},[],{"trials":1973,"activeCount":101},[],{"trials":1975,"activeCount":101},[1976],{"nctId":1977,"briefTitle":1978,"status":614,"phases":1979,"primaryCompletion":1980,"completion":829,"start":1981,"enrollment":23,"conditions":1982,"interventions":1984},"NCT00928798","Topical Rapamycin for Fibrofolliculomas",[91],"2011-02","2010-01",[1983],"Birt-Hogg-Dubé Syndrome",[1966],{"trials":1986,"activeCount":101},[],{"trials":1988,"activeCount":101},[],{"intervention":1990,"totalTrials":97,"cells":1991},"Ileocolonic release peppermint oil",{"EARLY_PHASE1":1992,"PHASE1":1994,"PHASE2":1996,"PHASE3":1998,"PHASE4":2013,"NA":2015},{"trials":1993,"activeCount":101},[],{"trials":1995,"activeCount":101},[],{"trials":1997,"activeCount":101},[],{"trials":1999,"activeCount":101},[2000],{"nctId":2001,"briefTitle":2002,"status":614,"phases":2003,"primaryCompletion":2004,"completion":2005,"start":2006,"enrollment":2007,"conditions":2008,"interventions":2011},"NCT02716285","Peppermint Oil for the Treatment of Irritable Bowel Syndrome: Optimizing Therapeutic Strategies Using Targeted Delivery",[91],"2018-05-01","2018-10-01","2016-08-17",190,[949,2009,2010],"Abdominal Pain","Colonic Diseases, Functional",[1990,2012],"Small intestinal release peppermint oil",{"trials":2014,"activeCount":101},[],{"trials":2016,"activeCount":101},[],{"intervention":2012,"totalTrials":97,"cells":2018},{"EARLY_PHASE1":2019,"PHASE1":2021,"PHASE2":2023,"PHASE3":2025,"PHASE4":2031,"NA":2033},{"trials":2020,"activeCount":101},[],{"trials":2022,"activeCount":101},[],{"trials":2024,"activeCount":101},[],{"trials":2026,"activeCount":101},[2027],{"nctId":2001,"briefTitle":2002,"status":614,"phases":2028,"primaryCompletion":2004,"completion":2005,"start":2006,"enrollment":2007,"conditions":2029,"interventions":2030},[91],[949,2009,2010],[1990,2012],{"trials":2032,"activeCount":101},[],{"trials":2034,"activeCount":101},[],{"intervention":2036,"totalTrials":97,"cells":2037},"Antioxidant",{"EARLY_PHASE1":2038,"PHASE1":2040,"PHASE2":2042,"PHASE3":2044,"PHASE4":2056,"NA":2058},{"trials":2039,"activeCount":101},[],{"trials":2041,"activeCount":101},[],{"trials":2043,"activeCount":101},[],{"trials":2045,"activeCount":101},[2046],{"nctId":2047,"briefTitle":2048,"status":278,"phases":2049,"primaryCompletion":1980,"start":2050,"enrollment":2051,"conditions":2052,"interventions":2054},"NCT00821158","The DIEP Flap as a Model of Ischemia-Reperfusion: an Intervention Study",[91],"2009-02",30,[2053],"Ischemia-Reperfusion",[2036,2055],"Anti-inflammatory drug",{"trials":2057,"activeCount":101},[],{"trials":2059,"activeCount":101},[],{"intervention":2055,"totalTrials":97,"cells":2061},{"EARLY_PHASE1":2062,"PHASE1":2064,"PHASE2":2066,"PHASE3":2068,"PHASE4":2074,"NA":2076},{"trials":2063,"activeCount":101},[],{"trials":2065,"activeCount":101},[],{"trials":2067,"activeCount":101},[],{"trials":2069,"activeCount":101},[2070],{"nctId":2047,"briefTitle":2048,"status":278,"phases":2071,"primaryCompletion":1980,"start":2050,"enrollment":2051,"conditions":2072,"interventions":2073},[91],[2053],[2036,2055],{"trials":2075,"activeCount":101},[],{"trials":2077,"activeCount":101},[],{"intervention":2079,"totalTrials":97,"cells":2080},"Sinecatechins 10%",{"EARLY_PHASE1":2081,"PHASE1":2083,"PHASE2":2085,"PHASE3":2087,"PHASE4":2097,"NA":2099},{"trials":2082,"activeCount":101},[],{"trials":2084,"activeCount":101},[],{"trials":2086,"activeCount":101},[],{"trials":2088,"activeCount":101},[2089],{"nctId":2090,"briefTitle":2091,"status":614,"phases":2092,"primaryCompletion":668,"completion":2093,"start":901,"enrollment":2094,"conditions":2095,"interventions":2096},"NCT02029352","Topical Green Tea Ointment in Treatment of Superficial Skin Cancer",[90,91],"2016-02",42,[575],[2079],{"trials":2098,"activeCount":101},[],{"trials":2100,"activeCount":101},[],{"intervention":2102,"totalTrials":97,"cells":2103},"Nortriptyline",{"EARLY_PHASE1":2104,"PHASE1":2106,"PHASE2":2108,"PHASE3":2110,"PHASE4":2122,"NA":2124},{"trials":2105,"activeCount":101},[],{"trials":2107,"activeCount":101},[],{"trials":2109,"activeCount":101},[],{"trials":2111,"activeCount":101},[2112],{"nctId":2113,"briefTitle":2114,"status":756,"phases":2115,"primaryCompletion":2116,"completion":2116,"start":2117,"enrollment":2118,"conditions":2119,"interventions":2121},"NCT03652571","Nortriptyline for the Treatment of Functional Dyspepsia",[91],"2024-08-01","2018-09-01",96,[2120],"Functional Dyspepsia",[2102],{"trials":2123,"activeCount":101},[],{"trials":2125,"activeCount":101},[],{"intervention":2127,"totalTrials":97,"cells":2128},"Extended-release Guanfacine Hydrochloride",{"EARLY_PHASE1":2129,"PHASE1":2131,"PHASE2":2133,"PHASE3":2135,"PHASE4":2147,"NA":2149},{"trials":2130,"activeCount":101},[],{"trials":2132,"activeCount":101},[],{"trials":2134,"activeCount":101},[],{"trials":2136,"activeCount":101},[2137],{"nctId":2138,"briefTitle":2139,"status":614,"phases":2140,"primaryCompletion":1130,"completion":2141,"start":2142,"enrollment":2143,"conditions":2144,"interventions":2146},"NCT03662763","Extended-release Guanfacine Hydrochloride in Children\u002FAdolescents With Attention-deficit\u002FHyperactivity",[91],"2013-12","2011-09",12,[2145],"Attention Deficit Disorder",[2127],{"trials":2148,"activeCount":101},[],{"trials":2150,"activeCount":101},[],{"intervention":2152,"totalTrials":603,"cells":2153},"Roflumilast Oral",{"EARLY_PHASE1":2154,"PHASE1":2156,"PHASE2":2158,"PHASE3":2193,"PHASE4":2195,"NA":2197},{"trials":2155,"activeCount":101},[],{"trials":2157,"activeCount":101},[],{"trials":2159,"activeCount":101},[2160,2172,2184],{"nctId":2161,"briefTitle":2162,"status":614,"phases":2163,"primaryCompletion":2164,"completion":2164,"start":2165,"enrollment":1760,"conditions":2166,"interventions":2171},"NCT04854811","Roflumilast to Treat Cognitive Sequela After Stroke",[90],"2023-12-01","2021-07-07",[2167,2168,2169,2170],"Cerebrovascular Disorders","Memory","Functional Recovery","Drug Intervention",[2152],{"nctId":2173,"briefTitle":2174,"status":278,"phases":2175,"primaryCompletion":2176,"completion":2176,"start":2177,"enrollment":2178,"conditions":2179,"interventions":2182},"NCT04658654","Cognitive Effects of Roflumilast in (a)MCI and Mild Dementia Patients",[90],"2023-10","2021-11-19",81,[1023,2180,2181],"Mild Dementia","Amnestic Mild Cognitive Disorder",[2183],"Roflumilast",{"nctId":2185,"briefTitle":2186,"status":614,"phases":2187,"primaryCompletion":1245,"completion":2188,"start":2142,"enrollment":12,"conditions":2189,"interventions":2191},"NCT01433666","Roflumilast and Cognition",[90],"2013-09",[2190],"Dementia",[2192,2192],"roflumilast",{"trials":2194,"activeCount":101},[],{"trials":2196,"activeCount":101},[],{"trials":2198,"activeCount":101},[],{"intervention":2200,"totalTrials":254,"cells":2201},"HBVaxPro",{"EARLY_PHASE1":2202,"PHASE1":2204,"PHASE2":2216,"PHASE3":2227,"PHASE4":2229,"NA":2231},{"trials":2203,"activeCount":101},[],{"trials":2205,"activeCount":101},[2206],{"nctId":2207,"briefTitle":2208,"status":614,"phases":2209,"primaryCompletion":2210,"completion":2210,"start":668,"enrollment":2211,"conditions":2212,"interventions":2214},"NCT02540538","Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders",[89],"2016-07",34,[2213],"Hepatitis B",[2200,2215],"HBAI20",{"trials":2217,"activeCount":101},[2218],{"nctId":2219,"briefTitle":2220,"status":614,"phases":2221,"primaryCompletion":2222,"completion":2222,"start":2223,"enrollment":2224,"conditions":2225,"interventions":2226},"NCT03415672","Hepatitis B Vaccine for Non-responders",[90],"2019-01-09","2017-10-11",133,[2213],[2200,2215],{"trials":2228,"activeCount":101},[],{"trials":2230,"activeCount":101},[],{"trials":2232,"activeCount":101},[],{"intervention":2215,"totalTrials":254,"cells":2234},{"EARLY_PHASE1":2235,"PHASE1":2237,"PHASE2":2243,"PHASE3":2249,"PHASE4":2251,"NA":2253},{"trials":2236,"activeCount":101},[],{"trials":2238,"activeCount":101},[2239],{"nctId":2207,"briefTitle":2208,"status":614,"phases":2240,"primaryCompletion":2210,"completion":2210,"start":668,"enrollment":2211,"conditions":2241,"interventions":2242},[89],[2213],[2200,2215],{"trials":2244,"activeCount":101},[2245],{"nctId":2219,"briefTitle":2220,"status":614,"phases":2246,"primaryCompletion":2222,"completion":2222,"start":2223,"enrollment":2224,"conditions":2247,"interventions":2248},[90],[2213],[2200,2215],{"trials":2250,"activeCount":101},[],{"trials":2252,"activeCount":101},[],{"trials":2254,"activeCount":101},[],{"intervention":633,"totalTrials":254,"cells":2256},{"EARLY_PHASE1":2257,"PHASE1":2259,"PHASE2":2261,"PHASE3":2274,"PHASE4":2276,"NA":2278},{"trials":2258,"activeCount":101},[],{"trials":2260,"activeCount":101},[],{"trials":2262,"activeCount":101},[2263,2267],{"nctId":625,"briefTitle":626,"status":614,"phases":2264,"primaryCompletion":628,"completion":628,"start":629,"enrollment":630,"conditions":2265,"interventions":2266},[90],[19],[633,602],{"nctId":2268,"briefTitle":2269,"status":614,"phases":2270,"primaryCompletion":280,"completion":280,"start":2271,"enrollment":1709,"conditions":2272,"interventions":2273},"NCT04921306","Obese Human Beta-2-adrenergic Stimulation and Muscle Glucose Uptake",[90],"2022-08-16",[1404],[633],{"trials":2275,"activeCount":101},[],{"trials":2277,"activeCount":101},[],{"trials":2279,"activeCount":101},[],{"intervention":623,"totalTrials":97,"cells":2281},{"EARLY_PHASE1":2282,"PHASE1":2284,"PHASE2":2286,"PHASE3":2292,"PHASE4":2294,"NA":2296},{"trials":2283,"activeCount":101},[],{"trials":2285,"activeCount":101},[],{"trials":2287,"activeCount":101},[2288],{"nctId":612,"briefTitle":613,"status":614,"phases":2289,"primaryCompletion":616,"completion":616,"start":617,"enrollment":618,"conditions":2290,"interventions":2291},[90],[620,621],[623,602],{"trials":2293,"activeCount":101},[],{"trials":2295,"activeCount":101},[],{"trials":2297,"activeCount":101},[],{"intervention":2299,"totalTrials":97,"cells":2300},"Diclofenac",{"EARLY_PHASE1":2301,"PHASE1":2303,"PHASE2":2305,"PHASE3":2319,"PHASE4":2321,"NA":2323},{"trials":2302,"activeCount":101},[],{"trials":2304,"activeCount":101},[],{"trials":2306,"activeCount":101},[2307],{"nctId":2308,"briefTitle":2309,"status":614,"phases":2310,"primaryCompletion":2311,"completion":2312,"start":2313,"enrollment":2314,"conditions":2315,"interventions":2316},"NCT01358045","Topical Vitamin D3, Diclofenac or a Combination of Both to Treat Basal Cell Carcinoma",[90],"2013-02","2013-05","2011-11",128,[570],[2299,2317,2318],"Diclofenac + Calcitriol","Calcitriol",{"trials":2320,"activeCount":101},[],{"trials":2322,"activeCount":101},[],{"trials":2324,"activeCount":101},[],{"intervention":2317,"totalTrials":97,"cells":2326},{"EARLY_PHASE1":2327,"PHASE1":2329,"PHASE2":2331,"PHASE3":2337,"PHASE4":2339,"NA":2341},{"trials":2328,"activeCount":101},[],{"trials":2330,"activeCount":101},[],{"trials":2332,"activeCount":101},[2333],{"nctId":2308,"briefTitle":2309,"status":614,"phases":2334,"primaryCompletion":2311,"completion":2312,"start":2313,"enrollment":2314,"conditions":2335,"interventions":2336},[90],[570],[2299,2317,2318],{"trials":2338,"activeCount":101},[],{"trials":2340,"activeCount":101},[],{"trials":2342,"activeCount":101},[],{"intervention":2318,"totalTrials":97,"cells":2344},{"EARLY_PHASE1":2345,"PHASE1":2347,"PHASE2":2349,"PHASE3":2355,"PHASE4":2357,"NA":2359},{"trials":2346,"activeCount":101},[],{"trials":2348,"activeCount":101},[],{"trials":2350,"activeCount":101},[2351],{"nctId":2308,"briefTitle":2309,"status":614,"phases":2352,"primaryCompletion":2311,"completion":2312,"start":2313,"enrollment":2314,"conditions":2353,"interventions":2354},[90],[570],[2299,2317,2318],{"trials":2356,"activeCount":101},[],{"trials":2358,"activeCount":101},[],{"trials":2360,"activeCount":101},[],{"intervention":2362,"totalTrials":97,"cells":2363},"Darleukin",{"EARLY_PHASE1":2364,"PHASE1":2366,"PHASE2":2368,"PHASE3":2380,"PHASE4":2382,"NA":2384},{"trials":2365,"activeCount":101},[],{"trials":2367,"activeCount":101},[],{"trials":2369,"activeCount":101},[2370],{"nctId":2371,"briefTitle":2372,"status":756,"phases":2373,"primaryCompletion":2374,"completion":2374,"start":2375,"enrollment":2376,"conditions":2377,"interventions":2379},"NCT03705403","IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study",[90],"2025-01-06","2019-04-04",88,[301,2378],"Metastatic Disease",[2362],{"trials":2381,"activeCount":101},[],{"trials":2383,"activeCount":101},[],{"trials":2385,"activeCount":101},[],{"intervention":2387,"totalTrials":97,"cells":2388},"celecoxib",{"EARLY_PHASE1":2389,"PHASE1":2391,"PHASE2":2393,"PHASE3":2403,"PHASE4":2405,"NA":2407},{"trials":2390,"activeCount":101},[],{"trials":2392,"activeCount":101},[],{"trials":2394,"activeCount":101},[2395],{"nctId":2396,"briefTitle":2397,"status":614,"phases":2398,"primaryCompletion":1561,"start":2399,"conditions":2400,"interventions":2402},"NCT01695226","Randomized Controlled Phase II Trial of Pre-operative Celecoxib Treatment in Breast Cancer",[90],"2004-02",[2401,27],"Breast Neoplasms",[2387],{"trials":2404,"activeCount":101},[],{"trials":2406,"activeCount":101},[],{"trials":2408,"activeCount":101},[],{"intervention":2410,"totalTrials":97,"cells":2411},"LSD",{"EARLY_PHASE1":2412,"PHASE1":2414,"PHASE2":2416,"PHASE3":2428,"PHASE4":2430,"NA":2432},{"trials":2413,"activeCount":101},[],{"trials":2415,"activeCount":101},[],{"trials":2417,"activeCount":101},[2418],{"nctId":2419,"briefTitle":2420,"status":278,"phases":2421,"primaryCompletion":2422,"completion":2422,"start":2423,"enrollment":161,"conditions":2424,"interventions":2426},"NCT05670184","The Effect of LSD on Neural Synchrony, Prosocial Behavior, and Relationship Quality",[89,90],"2024-01-01","2023-01-01",[2425],"Prosocial Behavior",[2410,2427],"Ethanol",{"trials":2429,"activeCount":101},[],{"trials":2431,"activeCount":101},[],{"trials":2433,"activeCount":101},[],{"intervention":2427,"totalTrials":97,"cells":2435},{"EARLY_PHASE1":2436,"PHASE1":2438,"PHASE2":2440,"PHASE3":2446,"PHASE4":2448,"NA":2450},{"trials":2437,"activeCount":101},[],{"trials":2439,"activeCount":101},[],{"trials":2441,"activeCount":101},[2442],{"nctId":2419,"briefTitle":2420,"status":278,"phases":2443,"primaryCompletion":2422,"completion":2422,"start":2423,"enrollment":161,"conditions":2444,"interventions":2445},[89,90],[2425],[2410,2427],{"trials":2447,"activeCount":101},[],{"trials":2449,"activeCount":101},[],{"trials":2451,"activeCount":101},[],{"intervention":2453,"totalTrials":97,"cells":2454},"Intra-arterial delivery of autologous MABs",{"EARLY_PHASE1":2455,"PHASE1":2457,"PHASE2":2459,"PHASE3":2470,"PHASE4":2472,"NA":2474},{"trials":2456,"activeCount":101},[],{"trials":2458,"activeCount":101},[],{"trials":2460,"activeCount":101},[2461],{"nctId":2462,"briefTitle":2463,"status":278,"phases":2464,"primaryCompletion":2116,"completion":2465,"start":2466,"enrollment":1402,"conditions":2467,"interventions":2469},"NCT05962333","Effect and Safety MABs Administration m.3243A>G Mutation Carriers",[90],"2025-02-01","2023-08-01",[2468],"Mitochondrial Myopathies",[2453],{"trials":2471,"activeCount":101},[],{"trials":2473,"activeCount":101},[],{"trials":2475,"activeCount":101},[],{"intervention":2477,"totalTrials":97,"cells":2478},"vaccination with Nicvax",{"EARLY_PHASE1":2479,"PHASE1":2481,"PHASE2":2483,"PHASE3":2495,"PHASE4":2497,"NA":2499},{"trials":2480,"activeCount":101},[],{"trials":2482,"activeCount":101},[],{"trials":2484,"activeCount":101},[2485],{"nctId":2486,"briefTitle":2487,"status":614,"phases":2488,"primaryCompletion":2489,"completion":2489,"start":1980,"enrollment":2490,"conditions":2491,"interventions":2494},"NCT01318668","A Fmri Study on the Effects of a Conjugate Vaccine and Placebo on CNS Activation and Behavior Following a Nicotine Challenge",[89,90],"2012-06",38,[2492,2493],"Nicotine Dependency","Smoking",[2477],{"trials":2496,"activeCount":101},[],{"trials":2498,"activeCount":101},[],{"trials":2500,"activeCount":101},[],{"intervention":2502,"totalTrials":97,"cells":2503},"Ketohexokinase inhibition",{"EARLY_PHASE1":2504,"PHASE1":2506,"PHASE2":2508,"PHASE3":2519,"PHASE4":2521,"NA":2523},{"trials":2505,"activeCount":101},[],{"trials":2507,"activeCount":101},[],{"trials":2509,"activeCount":101},[2510],{"nctId":2511,"briefTitle":2512,"status":614,"phases":2513,"primaryCompletion":2514,"completion":2514,"start":2515,"enrollment":34,"conditions":2516,"interventions":2518},"NCT05463575","Ketohexokinase Inhibition in NAFLD",[90],"2023-11-24","2022-10-01",[2517],"NAFLD",[2502],{"trials":2520,"activeCount":101},[],{"trials":2522,"activeCount":101},[],{"trials":2524,"activeCount":101},[],{"intervention":2526,"totalTrials":97,"cells":2527},"PF-06801591",{"EARLY_PHASE1":2528,"PHASE1":2530,"PHASE2":2532,"PHASE3":2543,"PHASE4":2545,"NA":2547},{"trials":2529,"activeCount":101},[],{"trials":2531,"activeCount":101},[],{"trials":2533,"activeCount":101},[2534],{"nctId":2535,"briefTitle":2536,"status":614,"phases":2537,"primaryCompletion":2538,"completion":2538,"start":2539,"enrollment":855,"conditions":2540,"interventions":2542},"NCT06089265","Ketohexokinase Inhibition in Hereditary Fructose Intolerance",[90],"2023-11-30","2023-06-15",[2541],"HFI",[2526],{"trials":2544,"activeCount":101},[],{"trials":2546,"activeCount":101},[],{"trials":2548,"activeCount":101},[],{"intervention":2550,"totalTrials":97,"cells":2551},"NicVAX vaccine",{"EARLY_PHASE1":2552,"PHASE1":2554,"PHASE2":2556,"PHASE3":2571,"PHASE4":2573,"NA":2575},{"trials":2553,"activeCount":101},[],{"trials":2555,"activeCount":101},[],{"trials":2557,"activeCount":101},[2558],{"nctId":2559,"briefTitle":2560,"status":614,"phases":2561,"primaryCompletion":2562,"completion":2562,"start":2563,"enrollment":2564,"conditions":2565,"interventions":2569},"NCT00995033","Efficacy and Safety of NicVAX® Co-administered With Varenicline (Champix®)",[90],"2012-09","2009-10",558,[2566,2567,2568],"Smoking Behavior","Smoking Lapse Behavior","Smoking Relapse Behavior",[2550,2570],"Varenicline",{"trials":2572,"activeCount":101},[],{"trials":2574,"activeCount":101},[],{"trials":2576,"activeCount":101},[],{"intervention":2570,"totalTrials":97,"cells":2578},{"EARLY_PHASE1":2579,"PHASE1":2581,"PHASE2":2583,"PHASE3":2589,"PHASE4":2591,"NA":2593},{"trials":2580,"activeCount":101},[],{"trials":2582,"activeCount":101},[],{"trials":2584,"activeCount":101},[2585],{"nctId":2559,"briefTitle":2560,"status":614,"phases":2586,"primaryCompletion":2562,"completion":2562,"start":2563,"enrollment":2564,"conditions":2587,"interventions":2588},[90],[2566,2567,2568],[2550,2570],{"trials":2590,"activeCount":101},[],{"trials":2592,"activeCount":101},[],{"trials":2594,"activeCount":101},[],{"intervention":2596,"totalTrials":97,"cells":2597},"Riociguat",{"EARLY_PHASE1":2598,"PHASE1":2600,"PHASE2":2602,"PHASE3":2617,"PHASE4":2619,"NA":2621},{"trials":2599,"activeCount":101},[],{"trials":2601,"activeCount":101},[],{"trials":2603,"activeCount":101},[2604],{"nctId":2605,"briefTitle":2606,"status":278,"phases":2607,"primaryCompletion":2608,"completion":2609,"start":2610,"enrollment":2611,"conditions":2612,"interventions":2614},"NCT05762146","Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE",[90],"2024-02-29","2024-04-30","2022-09-05",28,[2613],"Ischemic Stroke, Acute",[2596,2615,2616],"Propylthiouracil","Perphenazine",{"trials":2618,"activeCount":101},[],{"trials":2620,"activeCount":101},[],{"trials":2622,"activeCount":101},[],{"intervention":2615,"totalTrials":97,"cells":2624},{"EARLY_PHASE1":2625,"PHASE1":2627,"PHASE2":2629,"PHASE3":2635,"PHASE4":2637,"NA":2639},{"trials":2626,"activeCount":101},[],{"trials":2628,"activeCount":101},[],{"trials":2630,"activeCount":101},[2631],{"nctId":2605,"briefTitle":2606,"status":278,"phases":2632,"primaryCompletion":2608,"completion":2609,"start":2610,"enrollment":2611,"conditions":2633,"interventions":2634},[90],[2613],[2596,2615,2616],{"trials":2636,"activeCount":101},[],{"trials":2638,"activeCount":101},[],{"trials":2640,"activeCount":101},[],{"intervention":2616,"totalTrials":97,"cells":2642},{"EARLY_PHASE1":2643,"PHASE1":2645,"PHASE2":2647,"PHASE3":2653,"PHASE4":2655,"NA":2657},{"trials":2644,"activeCount":101},[],{"trials":2646,"activeCount":101},[],{"trials":2648,"activeCount":101},[2649],{"nctId":2605,"briefTitle":2606,"status":278,"phases":2650,"primaryCompletion":2608,"completion":2609,"start":2610,"enrollment":2611,"conditions":2651,"interventions":2652},[90],[2613],[2596,2615,2616],{"trials":2654,"activeCount":101},[],{"trials":2656,"activeCount":101},[],{"trials":2658,"activeCount":101},[],{"intervention":2660,"totalTrials":97,"cells":2661},"Menthae piperitae aetheroleum\u002Fpeppermint oil",{"EARLY_PHASE1":2662,"PHASE1":2664,"PHASE2":2666,"PHASE3":2677,"PHASE4":2679,"NA":2681},{"trials":2663,"activeCount":101},[],{"trials":2665,"activeCount":101},[],{"trials":2667,"activeCount":101},[2668],{"nctId":2669,"briefTitle":2670,"status":614,"phases":2671,"primaryCompletion":1086,"completion":668,"start":2672,"enrollment":855,"conditions":2673,"interventions":2676},"NCT02291445","Comparing a 182mg Colon-targeted-delivery Peppermint Oil Capsule (Tempocol-ColoPulse®) and a 182mg Enteric-coated Peppermint Oil Capsule (Tempocol®), a Pharmacokinetic Study",[90],"2015-03",[949,2009,2674,2675],"Colonic Diseases","Visceral Pain",[2660,2660],{"trials":2678,"activeCount":101},[],{"trials":2680,"activeCount":101},[],{"trials":2682,"activeCount":101},[],{"intervention":2684,"totalTrials":97,"cells":2685},"JDQ443",{"EARLY_PHASE1":2686,"PHASE1":2688,"PHASE2":2690,"PHASE3":2703,"PHASE4":2705,"NA":2707},{"trials":2687,"activeCount":101},[],{"trials":2689,"activeCount":101},[],{"trials":2691,"activeCount":101},[2692],{"nctId":2693,"briefTitle":2694,"status":997,"phases":2695,"primaryCompletion":2696,"completion":2697,"start":2698,"enrollment":101,"conditions":2699,"interventions":2702},"NCT05999357","JDQ443 for KRAS G12C NSCLC Brain Metastases",[90],"2027-08","2028-08","2024-04-15",[2700,302,2701],"Non Small Cell Lung Cancer Metastatic","KRAS G12C",[2684],{"trials":2704,"activeCount":101},[],{"trials":2706,"activeCount":101},[],{"trials":2708,"activeCount":101},[],{"intervention":2710,"totalTrials":97,"cells":2711},"Tacrolimus",{"EARLY_PHASE1":2712,"PHASE1":2714,"PHASE2":2724,"PHASE3":2726,"PHASE4":2728,"NA":2730},{"trials":2713,"activeCount":101},[],{"trials":2715,"activeCount":101},[2716],{"nctId":2717,"briefTitle":2718,"status":278,"phases":2719,"primaryCompletion":2142,"completion":2142,"start":2720,"enrollment":28,"conditions":2721,"interventions":2723},"NCT00987103","Pharmacokinetic Study to Rectal and Sublingual Administration of Tacrolimus in Future Kidney Transplant Patients",[89],"2009-09",[2722],"Organ Transplantation",[2710],{"trials":2725,"activeCount":101},[],{"trials":2727,"activeCount":101},[],{"trials":2729,"activeCount":101},[],{"trials":2731,"activeCount":101},[],{"intervention":2733,"totalTrials":97,"cells":2734},"Propylthiouracil, Riociguat, Perphenazine",{"EARLY_PHASE1":2735,"PHASE1":2737,"PHASE2":2749,"PHASE3":2751,"PHASE4":2753,"NA":2755},{"trials":2736,"activeCount":101},[],{"trials":2738,"activeCount":101},[2739],{"nctId":2740,"briefTitle":2741,"status":614,"phases":2742,"primaryCompletion":2743,"completion":2743,"start":2744,"enrollment":855,"conditions":2745,"interventions":2748},"NCT04776499","Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers",[89],"2022-02-28","2021-03-18",[2746,2747],"Drug Drug Interaction","Safety Issues",[2733],{"trials":2750,"activeCount":101},[],{"trials":2752,"activeCount":101},[],{"trials":2754,"activeCount":101},[],{"trials":2756,"activeCount":101},[],{"intervention":2758,"totalTrials":97,"cells":2759},"autologous mesoangioblasts",{"EARLY_PHASE1":2760,"PHASE1":2762,"PHASE2":2773,"PHASE3":2775,"PHASE4":2777,"NA":2779},{"trials":2761,"activeCount":101},[],{"trials":2763,"activeCount":101},[2764],{"nctId":2765,"briefTitle":2766,"status":614,"phases":2767,"primaryCompletion":2768,"completion":2769,"start":2770,"enrollment":830,"conditions":2771,"interventions":2772},"NCT05063721","MABs Therapy m.3243A>G Mutation Carriers",[89],"2022-09-16","2022-12-01","2020-03-01",[2468],[2758],{"trials":2774,"activeCount":101},[],{"trials":2776,"activeCount":101},[],{"trials":2778,"activeCount":101},[],{"trials":2780,"activeCount":101},[],{"intervention":2782,"totalTrials":97,"cells":2783},"Intravenous immunoglobulin therapy",{"EARLY_PHASE1":2784,"PHASE1":2786,"PHASE2":2797,"PHASE3":2799,"PHASE4":2801,"NA":2803},{"trials":2785,"activeCount":101},[],{"trials":2787,"activeCount":101},[2788],{"nctId":2789,"briefTitle":2790,"status":278,"phases":2791,"primaryCompletion":2792,"completion":2793,"start":2050,"enrollment":524,"conditions":2794,"interventions":2796},"NCT00659386","IVIg Therapy for Patients With Idiopathic Cardiomyopathy and Endomyocardial Biopsy Proven High PVB19 Viral Load",[89],"2010-02","2010-08",[2795],"Heart Failure",[2782],{"trials":2798,"activeCount":101},[],{"trials":2800,"activeCount":101},[],{"trials":2802,"activeCount":101},[],{"trials":2804,"activeCount":101},[],{"intervention":2806,"totalTrials":97,"cells":2807},"indometacin",{"EARLY_PHASE1":2808,"PHASE1":2818,"PHASE2":2820,"PHASE3":2822,"PHASE4":2824,"NA":2826},{"trials":2809,"activeCount":101},[2810],{"nctId":2811,"briefTitle":2812,"status":278,"phases":2813,"primaryCompletion":2814,"completion":2814,"start":2720,"enrollment":2211,"conditions":2815,"interventions":2817},"NCT00943345","Validation of New Tests for Gastrointestinal (GI) Permeability",[88],"2012-02",[2816],"Gastrointestinal Diseases",[2806],{"trials":2819,"activeCount":101},[],{"trials":2821,"activeCount":101},[],{"trials":2823,"activeCount":101},[],{"trials":2825,"activeCount":101},[],{"trials":2827,"activeCount":101},[],{"intervention":2829,"totalTrials":97,"cells":2830},"Pilocarpine Ophthalmic Solution",{"EARLY_PHASE1":2831,"PHASE1":2843,"PHASE2":2845,"PHASE3":2847,"PHASE4":2849,"NA":2851},{"trials":2832,"activeCount":101},[2833],{"nctId":2834,"briefTitle":2835,"status":614,"phases":2836,"primaryCompletion":2837,"completion":2838,"start":2839,"enrollment":1709,"conditions":2840,"interventions":2842},"NCT04195100","Local Pilocarpine for Relieving Dry Mouth",[88],"2019-12-01","2020-01-31","2019-04-01",[2841],"Patients of Advanced Age (≥ 70 Years) With a Clinical Diagnosis of Chronic Dry Mouth",[2829],{"trials":2844,"activeCount":101},[],{"trials":2846,"activeCount":101},[],{"trials":2848,"activeCount":101},[],{"trials":2850,"activeCount":101},[],{"trials":2852,"activeCount":101},[],{"intervention":906,"totalTrials":603,"cells":2854},{"EARLY_PHASE1":2855,"PHASE1":2857,"PHASE2":2859,"PHASE3":2861,"PHASE4":2872,"NA":2878},{"trials":2856,"activeCount":101},[],{"trials":2858,"activeCount":101},[],{"trials":2860,"activeCount":101},[],{"trials":2862,"activeCount":101},[2863],{"nctId":2864,"briefTitle":2865,"status":756,"phases":2866,"primaryCompletion":2867,"completion":2867,"start":731,"enrollment":2868,"conditions":2869,"interventions":2871},"NCT02329171","Imiquimod Treatment of CIN Lesions",[91],"2016-06",9,[2870],"Cervical Intraepithelial Neoplasia",[906],{"trials":2873,"activeCount":101},[2874],{"nctId":896,"briefTitle":897,"status":278,"phases":2875,"primaryCompletion":899,"completion":900,"start":901,"enrollment":902,"conditions":2876,"interventions":2877},[92],[904],[906,883,907],{"trials":2879,"activeCount":101},[2880],{"nctId":2881,"briefTitle":2882,"status":278,"phases":2883,"primaryCompletion":899,"completion":784,"start":2884,"enrollment":1662,"conditions":2885,"interventions":2886},"NCT02917746","Imiquimod Treatment of High-grade CIN",[93],"2016-11",[2870],[906],{"intervention":2888,"totalTrials":254,"cells":2889},"Influenza vaccine",{"EARLY_PHASE1":2890,"PHASE1":2892,"PHASE2":2894,"PHASE3":2896,"PHASE4":2898,"NA":2900},{"trials":2891,"activeCount":101},[],{"trials":2893,"activeCount":101},[],{"trials":2895,"activeCount":101},[],{"trials":2897,"activeCount":101},[],{"trials":2899,"activeCount":101},[],{"trials":2901,"activeCount":101},[2902,2912],{"nctId":2903,"briefTitle":2904,"status":614,"phases":2905,"primaryCompletion":2906,"completion":2906,"start":2907,"enrollment":2908,"conditions":2909,"interventions":2911},"NCT05706350","Plant Stanol Esters and Influenza Vaccination",[93],"2022-12-20","2022-10-11",137,[2910],"Immune Response",[2888],{"nctId":2913,"briefTitle":2914,"status":614,"phases":2915,"primaryCompletion":2916,"completion":2917,"start":2918,"enrollment":2376,"conditions":2919,"interventions":2920},"NCT06041867","Agaricus Bisporus and Influenza Vaccination Response",[93],"2023-12-15","2024-05-30","2023-09-14",[2910],[2888],{"intervention":2922,"totalTrials":254,"cells":2923},"Amoxicillin",{"EARLY_PHASE1":2924,"PHASE1":2926,"PHASE2":2928,"PHASE3":2930,"PHASE4":2932,"NA":2934},{"trials":2925,"activeCount":101},[],{"trials":2927,"activeCount":101},[],{"trials":2929,"activeCount":101},[],{"trials":2931,"activeCount":101},[],{"trials":2933,"activeCount":101},[],{"trials":2935,"activeCount":101},[2936,2946],{"nctId":2937,"briefTitle":2938,"status":614,"phases":2939,"primaryCompletion":2940,"completion":2940,"start":2941,"enrollment":2942,"conditions":2943,"interventions":2945},"NCT01566266","Gut Flora and Lipid Metabolism",[93],"2013-04","2012-03",77,[2944],"Hypercholesterolemia",[2922],{"nctId":2947,"briefTitle":2948,"status":614,"phases":2949,"primaryCompletion":1244,"completion":901,"start":2950,"enrollment":2951,"conditions":2952,"interventions":2953},"NCT02241421","The Importance of the Gut Microbiota in Body Weight Control and Insulin Sensitivity",[93],"2012-04",57,[16,22],[2922,2954],"Vancomycin",{"intervention":2956,"totalTrials":97,"cells":2957},"cetirizine 10 mg",{"EARLY_PHASE1":2958,"PHASE1":2960,"PHASE2":2962,"PHASE3":2964,"PHASE4":2966,"NA":2968},{"trials":2959,"activeCount":101},[],{"trials":2961,"activeCount":101},[],{"trials":2963,"activeCount":101},[],{"trials":2965,"activeCount":101},[],{"trials":2967,"activeCount":101},[],{"trials":2969,"activeCount":101},[2970],{"nctId":2971,"briefTitle":2972,"status":614,"phases":2973,"primaryCompletion":2941,"completion":1045,"start":2974,"enrollment":12,"conditions":2975,"interventions":2979},"NCT01318681","Rhinitis, Cognition and Driving Performance",[93],"2011-01",[2976,2977,2978],"Seasonal Allergic Rhinitis","Driving Ability","Cognition",[2956,2980],"fluticasone furoate",{"intervention":2980,"totalTrials":97,"cells":2982},{"EARLY_PHASE1":2983,"PHASE1":2985,"PHASE2":2987,"PHASE3":2989,"PHASE4":2991,"NA":2993},{"trials":2984,"activeCount":101},[],{"trials":2986,"activeCount":101},[],{"trials":2988,"activeCount":101},[],{"trials":2990,"activeCount":101},[],{"trials":2992,"activeCount":101},[],{"trials":2994,"activeCount":101},[2995],{"nctId":2971,"briefTitle":2972,"status":614,"phases":2996,"primaryCompletion":2941,"completion":1045,"start":2974,"enrollment":12,"conditions":2997,"interventions":2998},[93],[2976,2977,2978],[2956,2980],{"intervention":3000,"totalTrials":97,"cells":3001},"JWH018",{"EARLY_PHASE1":3002,"PHASE1":3004,"PHASE2":3006,"PHASE3":3008,"PHASE4":3010,"NA":3012},{"trials":3003,"activeCount":101},[],{"trials":3005,"activeCount":101},[],{"trials":3007,"activeCount":101},[],{"trials":3009,"activeCount":101},[],{"trials":3011,"activeCount":101},[],{"trials":3013,"activeCount":101},[3014],{"nctId":3015,"briefTitle":3016,"status":278,"phases":3017,"primaryCompletion":3018,"completion":3018,"start":2176,"enrollment":3019,"conditions":3020,"interventions":3022},"NCT06044415","Brain Activity Under the Influence of JWH",[93],"2024-10",24,[3021],"Neurotransmission During JWH Intoxication",[3000],{"intervention":3024,"totalTrials":97,"cells":3025},"Ropivacaine\u002F Sufentanil according to local hospital protocol",{"EARLY_PHASE1":3026,"PHASE1":3028,"PHASE2":3030,"PHASE3":3032,"PHASE4":3034,"NA":3036},{"trials":3027,"activeCount":101},[],{"trials":3029,"activeCount":101},[],{"trials":3031,"activeCount":101},[],{"trials":3033,"activeCount":101},[],{"trials":3035,"activeCount":101},[],{"trials":3037,"activeCount":101},[3038],{"nctId":3039,"briefTitle":3040,"status":614,"phases":3041,"primaryCompletion":1044,"completion":1044,"start":3042,"enrollment":3043,"conditions":3044,"interventions":3049},"NCT01261689","The Randomised Epidural Analgesia in Term Delivering Women Trial (TREAT)",[93],"2008-09",488,[3045,3046,3047,3048],"Analgesia, Epidural","Instrumental Delivery","Maternal Outcome","Neonatal Outcome",[3024],{"intervention":3051,"totalTrials":97,"cells":3052},"follitropin and lutropin",{"EARLY_PHASE1":3053,"PHASE1":3055,"PHASE2":3057,"PHASE3":3059,"PHASE4":3061,"NA":3063},{"trials":3054,"activeCount":101},[],{"trials":3056,"activeCount":101},[],{"trials":3058,"activeCount":101},[],{"trials":3060,"activeCount":101},[],{"trials":3062,"activeCount":101},[],{"trials":3064,"activeCount":101},[3065],{"nctId":3066,"briefTitle":3067,"status":278,"phases":3068,"primaryCompletion":3069,"start":3070,"enrollment":299,"conditions":3071,"interventions":3074},"NCT00619333","Inactive FSH in Galactosemia",[93],"2010-03","2007-03",[3072,3073],"Galactosemia","Premature Ovarian Failure",[3051],{"intervention":3076,"totalTrials":97,"cells":3077},"acenocoumarol",{"EARLY_PHASE1":3078,"PHASE1":3080,"PHASE2":3082,"PHASE3":3084,"PHASE4":3086,"NA":3088},{"trials":3079,"activeCount":101},[],{"trials":3081,"activeCount":101},[],{"trials":3083,"activeCount":101},[],{"trials":3085,"activeCount":101},[],{"trials":3087,"activeCount":101},[],{"trials":3089,"activeCount":101},[3090],{"nctId":3091,"briefTitle":3092,"status":614,"phases":3093,"primaryCompletion":3094,"completion":3094,"start":3095,"enrollment":1402,"conditions":3096,"interventions":3097},"NCT00512928","Safety Study of Vitamin K2 During Anticoagulation in Human Volunteers",[93],"2007-12","2007-09",[19],[3076],{"intervention":3099,"totalTrials":97,"cells":3100},"Gadofosveset contrast agent enhanced MRI Axilla",{"EARLY_PHASE1":3101,"PHASE1":3103,"PHASE2":3105,"PHASE3":3107,"PHASE4":3109,"NA":3111},{"trials":3102,"activeCount":101},[],{"trials":3104,"activeCount":101},[],{"trials":3106,"activeCount":101},[],{"trials":3108,"activeCount":101},[],{"trials":3110,"activeCount":101},[],{"trials":3112,"activeCount":101},[3113],{"nctId":3114,"briefTitle":3115,"status":614,"phases":3116,"primaryCompletion":2814,"completion":2941,"start":2142,"enrollment":3117,"conditions":3118,"interventions":3119},"NCT01437865","Gadofosveset for Axillary Staging in Breast Cancer Patients",[93],10,[2401],[3099],{"intervention":3121,"totalTrials":97,"cells":3122},"Trastuzumab",{"EARLY_PHASE1":3123,"PHASE1":3125,"PHASE2":3127,"PHASE3":3129,"PHASE4":3131,"NA":3133},{"trials":3124,"activeCount":101},[],{"trials":3126,"activeCount":101},[],{"trials":3128,"activeCount":101},[],{"trials":3130,"activeCount":101},[],{"trials":3132,"activeCount":101},[],{"trials":3134,"activeCount":101},[3135],{"nctId":3136,"briefTitle":3137,"status":614,"phases":3138,"primaryCompletion":3139,"completion":2312,"start":3140,"enrollment":3141,"conditions":3142,"interventions":3143},"NCT01894711","Real World Efficiency of Trastuzumab in Early Breast Cancer",[],"2012-11","2010-05",2684,[27],[3121],{"intervention":3145,"totalTrials":97,"cells":3146},"Irbesartan",{"EARLY_PHASE1":3147,"PHASE1":3149,"PHASE2":3151,"PHASE3":3153,"PHASE4":3155,"NA":3157},{"trials":3148,"activeCount":101},[],{"trials":3150,"activeCount":101},[],{"trials":3152,"activeCount":101},[],{"trials":3154,"activeCount":101},[],{"trials":3156,"activeCount":101},[],{"trials":3158,"activeCount":101},[3159],{"nctId":3160,"briefTitle":3161,"status":278,"phases":3162,"primaryCompletion":3163,"completion":3163,"start":3164,"enrollment":947,"conditions":3165,"interventions":3167},"NCT00742066","Role of AT1-receptor Blockers in Insulin-induced Vasodilation.",[93],"2009-07","2008-03",[762,22,3166],"Microcirculation",[3145,3168],"Felodipine",{"intervention":3168,"totalTrials":97,"cells":3170},{"EARLY_PHASE1":3171,"PHASE1":3173,"PHASE2":3175,"PHASE3":3177,"PHASE4":3179,"NA":3181},{"trials":3172,"activeCount":101},[],{"trials":3174,"activeCount":101},[],{"trials":3176,"activeCount":101},[],{"trials":3178,"activeCount":101},[],{"trials":3180,"activeCount":101},[],{"trials":3182,"activeCount":101},[3183],{"nctId":3160,"briefTitle":3161,"status":278,"phases":3184,"primaryCompletion":3163,"completion":3163,"start":3164,"enrollment":947,"conditions":3185,"interventions":3186},[93],[762,22,3166],[3145,3168],{"intervention":3188,"totalTrials":97,"cells":3189},"Antihypertensive medication",{"EARLY_PHASE1":3190,"PHASE1":3192,"PHASE2":3194,"PHASE3":3196,"PHASE4":3198,"NA":3200},{"trials":3191,"activeCount":101},[],{"trials":3193,"activeCount":101},[],{"trials":3195,"activeCount":101},[],{"trials":3197,"activeCount":101},[],{"trials":3199,"activeCount":101},[],{"trials":3201,"activeCount":101},[3202],{"nctId":3203,"briefTitle":3204,"status":997,"phases":3205,"primaryCompletion":3206,"completion":3206,"start":545,"enrollment":101,"conditions":3207,"interventions":3210},"NCT02096939","Microvascular Function in Primary Aldosteronism",[],"2016-04",[3208,3209],"Primary Aldosteronism","Essential Hypertension",[3188],{"intervention":3212,"totalTrials":97,"cells":3213},"sulphur hexafluoride, gadopentate dimeglumine",{"EARLY_PHASE1":3214,"PHASE1":3216,"PHASE2":3218,"PHASE3":3220,"PHASE4":3222,"NA":3224},{"trials":3215,"activeCount":101},[],{"trials":3217,"activeCount":101},[],{"trials":3219,"activeCount":101},[],{"trials":3221,"activeCount":101},[],{"trials":3223,"activeCount":101},[],{"trials":3225,"activeCount":101},[3226],{"nctId":3227,"briefTitle":3228,"status":614,"phases":3229,"primaryCompletion":3230,"completion":3230,"start":3231,"enrollment":28,"conditions":3232,"interventions":3234},"NCT00677963","Contrast-enhanced Ultrasound (CE-US) and Magnetic Resonance Imaging (MRI): Evaluating Plaque Neovascularisation",[93],"2010-04","2009-06",[3233,505],"Carotid Artery Stenosis",[3212],{"intervention":3236,"totalTrials":97,"cells":3237},"Methylphenidate 40 mg",{"EARLY_PHASE1":3238,"PHASE1":3240,"PHASE2":3242,"PHASE3":3244,"PHASE4":3246,"NA":3248},{"trials":3239,"activeCount":101},[],{"trials":3241,"activeCount":101},[],{"trials":3243,"activeCount":101},[],{"trials":3245,"activeCount":101},[],{"trials":3247,"activeCount":101},[],{"trials":3249,"activeCount":101},[3250],{"nctId":3251,"briefTitle":3252,"status":614,"phases":3253,"primaryCompletion":2489,"completion":2489,"start":3254,"enrollment":1402,"conditions":3255,"interventions":3259},"NCT01218425","Dopaminergic Modulation of Cognition and Psychomotor Function",[93],"2010-11",[3256,3257,3258],"Dopamine Activity","Episodic Memory Consolidation","Response Preparation",[3236,3260,3261],"Levodopa\u002Fcarbidopa 125 mg","Domperidon 10 mg",{"intervention":3260,"totalTrials":97,"cells":3263},{"EARLY_PHASE1":3264,"PHASE1":3266,"PHASE2":3268,"PHASE3":3270,"PHASE4":3272,"NA":3274},{"trials":3265,"activeCount":101},[],{"trials":3267,"activeCount":101},[],{"trials":3269,"activeCount":101},[],{"trials":3271,"activeCount":101},[],{"trials":3273,"activeCount":101},[],{"trials":3275,"activeCount":101},[3276],{"nctId":3251,"briefTitle":3252,"status":614,"phases":3277,"primaryCompletion":2489,"completion":2489,"start":3254,"enrollment":1402,"conditions":3278,"interventions":3279},[93],[3256,3257,3258],[3236,3260,3261],{"intervention":3261,"totalTrials":97,"cells":3281},{"EARLY_PHASE1":3282,"PHASE1":3284,"PHASE2":3286,"PHASE3":3288,"PHASE4":3290,"NA":3292},{"trials":3283,"activeCount":101},[],{"trials":3285,"activeCount":101},[],{"trials":3287,"activeCount":101},[],{"trials":3289,"activeCount":101},[],{"trials":3291,"activeCount":101},[],{"trials":3293,"activeCount":101},[3294],{"nctId":3251,"briefTitle":3252,"status":614,"phases":3295,"primaryCompletion":2489,"completion":2489,"start":3254,"enrollment":1402,"conditions":3296,"interventions":3297},[93],[3256,3257,3258],[3236,3260,3261],{"intervention":3299,"totalTrials":97,"cells":3300},"Gadofosveset enhanced MRL of axillary lymph nodes",{"EARLY_PHASE1":3301,"PHASE1":3303,"PHASE2":3305,"PHASE3":3307,"PHASE4":3309,"NA":3311},{"trials":3302,"activeCount":101},[],{"trials":3304,"activeCount":101},[],{"trials":3306,"activeCount":101},[],{"trials":3308,"activeCount":101},[],{"trials":3310,"activeCount":101},[],{"trials":3312,"activeCount":101},[3313],{"nctId":3314,"briefTitle":3315,"status":756,"phases":3316,"primaryCompletion":3317,"completion":3317,"start":3318,"enrollment":3319,"conditions":3320,"interventions":3321},"NCT01609920","Nodal Staging in Breast Cancer With MRL",[93],"2016-05","2012-05",97,[2401],[3299],{"intervention":3323,"totalTrials":97,"cells":3324},"Standard protein enteral nutrition with enteral tracer",{"EARLY_PHASE1":3325,"PHASE1":3327,"PHASE2":3329,"PHASE3":3331,"PHASE4":3333,"NA":3335},{"trials":3326,"activeCount":101},[],{"trials":3328,"activeCount":101},[],{"trials":3330,"activeCount":101},[],{"trials":3332,"activeCount":101},[],{"trials":3334,"activeCount":101},[],{"trials":3336,"activeCount":101},[3337],{"nctId":3338,"briefTitle":3339,"status":614,"phases":3340,"primaryCompletion":3341,"completion":3341,"start":3342,"enrollment":855,"conditions":3343,"interventions":3346},"NCT06104527","Indicator Amino Acid Oxidation in ICU Patients",[93],"2026-03-23","2023-10-30",[3344,3345],"Critical Illness","Muscle Wasting",[3323,3347],"High protein enteral nutrition with enteral tracer",{"intervention":3347,"totalTrials":97,"cells":3349},{"EARLY_PHASE1":3350,"PHASE1":3352,"PHASE2":3354,"PHASE3":3356,"PHASE4":3358,"NA":3360},{"trials":3351,"activeCount":101},[],{"trials":3353,"activeCount":101},[],{"trials":3355,"activeCount":101},[],{"trials":3357,"activeCount":101},[],{"trials":3359,"activeCount":101},[],{"trials":3361,"activeCount":101},[3362],{"nctId":3338,"briefTitle":3339,"status":614,"phases":3363,"primaryCompletion":3341,"completion":3341,"start":3342,"enrollment":855,"conditions":3364,"interventions":3365},[93],[3344,3345],[3323,3347],{"intervention":3367,"totalTrials":97,"cells":3368},"Angiotensin II",{"EARLY_PHASE1":3369,"PHASE1":3371,"PHASE2":3373,"PHASE3":3375,"PHASE4":3377,"NA":3379},{"trials":3370,"activeCount":101},[],{"trials":3372,"activeCount":101},[],{"trials":3374,"activeCount":101},[],{"trials":3376,"activeCount":101},[],{"trials":3378,"activeCount":101},[],{"trials":3380,"activeCount":101},[3381],{"nctId":3382,"briefTitle":3383,"status":614,"phases":3384,"primaryCompletion":3385,"completion":3385,"start":1758,"enrollment":28,"conditions":3386,"interventions":3388},"NCT01024543","Role of Angiotensin II in Insulin-induced Microvascular Activity",[93],"2009-11",[3387,3166],"Insulin Sensitivity",[3367,3389],"Phenylephrine",{"intervention":3389,"totalTrials":97,"cells":3391},{"EARLY_PHASE1":3392,"PHASE1":3394,"PHASE2":3396,"PHASE3":3398,"PHASE4":3400,"NA":3402},{"trials":3393,"activeCount":101},[],{"trials":3395,"activeCount":101},[],{"trials":3397,"activeCount":101},[],{"trials":3399,"activeCount":101},[],{"trials":3401,"activeCount":101},[],{"trials":3403,"activeCount":101},[3404],{"nctId":3382,"briefTitle":3383,"status":614,"phases":3405,"primaryCompletion":3385,"completion":3385,"start":1758,"enrollment":28,"conditions":3406,"interventions":3407},[93],[3387,3166],[3367,3389],{"intervention":3409,"totalTrials":97,"cells":3410},"Imiquimod Topical",{"EARLY_PHASE1":3411,"PHASE1":3413,"PHASE2":3415,"PHASE3":3417,"PHASE4":3419,"NA":3421},{"trials":3412,"activeCount":101},[],{"trials":3414,"activeCount":101},[],{"trials":3416,"activeCount":101},[],{"trials":3418,"activeCount":101},[],{"trials":3420,"activeCount":101},[],{"trials":3422,"activeCount":101},[3423],{"nctId":3424,"briefTitle":3425,"status":278,"phases":3426,"primaryCompletion":352,"completion":352,"start":3427,"enrollment":3428,"conditions":3429,"interventions":3430},"NCT06252857","Real-world Evaluation of Diagnostic and Treatment Strategies in Low-Risk Basal Cell Carcinoma",[],"2024-04-22",142,[570],[3409],{"intervention":3432,"totalTrials":97,"cells":3433},"tailored pharmaceutical treatment",{"EARLY_PHASE1":3434,"PHASE1":3436,"PHASE2":3438,"PHASE3":3440,"PHASE4":3442,"NA":3444},{"trials":3435,"activeCount":101},[],{"trials":3437,"activeCount":101},[],{"trials":3439,"activeCount":101},[],{"trials":3441,"activeCount":101},[],{"trials":3443,"activeCount":101},[],{"trials":3445,"activeCount":101},[3446],{"nctId":3447,"briefTitle":3448,"status":614,"phases":3449,"primaryCompletion":3450,"completion":2770,"start":3451,"enrollment":3452,"conditions":3453,"interventions":3457},"NCT04216706","Early Vascular Adjustments to Prevent Preeclampsia",[],"2020-01-01","2014-11-01",314,[3454,3455,3456],"Preeclampsia","Small for Gestational Age at Delivery","HELLP Syndrome",[3432],{"intervention":3459,"totalTrials":97,"cells":3460},"Acipimox",{"EARLY_PHASE1":3461,"PHASE1":3463,"PHASE2":3465,"PHASE3":3467,"PHASE4":3469,"NA":3471},{"trials":3462,"activeCount":101},[],{"trials":3464,"activeCount":101},[],{"trials":3466,"activeCount":101},[],{"trials":3468,"activeCount":101},[],{"trials":3470,"activeCount":101},[],{"trials":3472,"activeCount":101},[3473],{"nctId":3474,"briefTitle":3475,"status":614,"phases":3476,"primaryCompletion":828,"completion":828,"start":3069,"enrollment":3477,"conditions":3478,"interventions":3481},"NCT00943059","Cross-over Study on Effect of Lipid Lowering by Acipimox on Cardiac and Skeletal Muscle Mitochondrial Function",[93],31,[3479,3480],"Diabetes Mellitus, Type 2","Cardiomyopathy, Dilated",[3459,3482],"Cellulosum Mycrocryst",{"intervention":3482,"totalTrials":97,"cells":3484},{"EARLY_PHASE1":3485,"PHASE1":3487,"PHASE2":3489,"PHASE3":3491,"PHASE4":3493,"NA":3495},{"trials":3486,"activeCount":101},[],{"trials":3488,"activeCount":101},[],{"trials":3490,"activeCount":101},[],{"trials":3492,"activeCount":101},[],{"trials":3494,"activeCount":101},[],{"trials":3496,"activeCount":101},[3497],{"nctId":3474,"briefTitle":3475,"status":614,"phases":3498,"primaryCompletion":828,"completion":828,"start":3069,"enrollment":3477,"conditions":3499,"interventions":3500},[93],[3479,3480],[3459,3482],{"intervention":3502,"totalTrials":97,"cells":3503},"GADOFOSVESET TRISODIUM 244 Mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Ablavar]",{"EARLY_PHASE1":3504,"PHASE1":3506,"PHASE2":3508,"PHASE3":3510,"PHASE4":3512,"NA":3514},{"trials":3505,"activeCount":101},[],{"trials":3507,"activeCount":101},[],{"trials":3509,"activeCount":101},[],{"trials":3511,"activeCount":101},[],{"trials":3513,"activeCount":101},[],{"trials":3515,"activeCount":101},[3516],{"nctId":3517,"briefTitle":3518,"status":614,"phases":3519,"primaryCompletion":2210,"completion":2210,"start":1045,"enrollment":3520,"conditions":3521,"interventions":3525},"NCT01721785","Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer",[],307,[3522,3523,3524],"Rectal Neoplasms","Magnetic Resonance Imaging","Neoplasms Staging",[3502],{"intervention":3527,"totalTrials":97,"cells":3528},"dexchlorpheniramine, lorazepam",{"EARLY_PHASE1":3529,"PHASE1":3531,"PHASE2":3533,"PHASE3":3535,"PHASE4":3537,"NA":3539},{"trials":3530,"activeCount":101},[],{"trials":3532,"activeCount":101},[],{"trials":3534,"activeCount":101},[],{"trials":3536,"activeCount":101},[],{"trials":3538,"activeCount":101},[],{"trials":3540,"activeCount":101},[3541],{"nctId":3542,"briefTitle":3543,"status":614,"phases":3544,"primaryCompletion":1894,"completion":1894,"start":3545,"enrollment":28,"conditions":3546,"interventions":3547},"NCT00846950","Effects of H1-Antagonist on Cognition",[93],"2006-12",[2978],[3527],{"intervention":3549,"totalTrials":97,"cells":3550},"Carnitene",{"EARLY_PHASE1":3551,"PHASE1":3553,"PHASE2":3555,"PHASE3":3557,"PHASE4":3559,"NA":3561},{"trials":3552,"activeCount":101},[],{"trials":3554,"activeCount":101},[],{"trials":3556,"activeCount":101},[],{"trials":3558,"activeCount":101},[],{"trials":3560,"activeCount":101},[],{"trials":3562,"activeCount":101},[3563],{"nctId":3564,"briefTitle":3565,"status":614,"phases":3566,"primaryCompletion":3567,"completion":3567,"start":3568,"enrollment":947,"conditions":3569,"interventions":3570},"NCT03230812","Carnitine Supplementation in Type 2 Diabetic Patients",[93],"2019-11-11","2018-03-01",[1637],[3549],{"intervention":3572,"totalTrials":97,"cells":3573},"Butyrate",{"EARLY_PHASE1":3574,"PHASE1":3576,"PHASE2":3578,"PHASE3":3580,"PHASE4":3582,"NA":3584},{"trials":3575,"activeCount":101},[],{"trials":3577,"activeCount":101},[],{"trials":3579,"activeCount":101},[],{"trials":3581,"activeCount":101},[],{"trials":3583,"activeCount":101},[],{"trials":3585,"activeCount":101},[3586],{"nctId":3587,"briefTitle":3588,"status":614,"phases":3589,"primaryCompletion":3590,"start":3094,"enrollment":630,"conditions":3591,"interventions":3593},"NCT00726817","The Effects of Butyrate Enemas on Visceral Perception",[93],"2008-02",[3592],"Visceral (Hyper)Sensitivity",[3572],{"intervention":3595,"totalTrials":97,"cells":3596},"Genetic analysis for PCSK9 polymorphisms",{"EARLY_PHASE1":3597,"PHASE1":3599,"PHASE2":3601,"PHASE3":3603,"PHASE4":3605,"NA":3607},{"trials":3598,"activeCount":101},[],{"trials":3600,"activeCount":101},[],{"trials":3602,"activeCount":101},[],{"trials":3604,"activeCount":101},[],{"trials":3606,"activeCount":101},[],{"trials":3608,"activeCount":101},[3609],{"nctId":3610,"briefTitle":3611,"status":278,"phases":3612,"primaryCompletion":3613,"completion":3614,"start":3615,"enrollment":1760,"conditions":3616,"interventions":3619},"NCT05503095","PCSK9 Polymorphism and Risk of Cardiac Rupture",[],"2023-08-31","2024-05-31","2022-01-01",[3617,3618],"Post-Infarction Heart Rupture","Gene Polymorphism",[3595],{"intervention":3621,"totalTrials":97,"cells":3622},"beclomethasondipropionate",{"EARLY_PHASE1":3623,"PHASE1":3625,"PHASE2":3627,"PHASE3":3629,"PHASE4":3631,"NA":3633},{"trials":3624,"activeCount":101},[],{"trials":3626,"activeCount":101},[],{"trials":3628,"activeCount":101},[],{"trials":3630,"activeCount":101},[],{"trials":3632,"activeCount":101},[],{"trials":3634,"activeCount":101},[3635],{"nctId":3636,"briefTitle":3637,"status":614,"phases":3638,"primaryCompletion":732,"completion":1131,"start":3639,"enrollment":3640,"conditions":3641,"interventions":3643},"NCT00422747","Early Diagnosis of Asthma in Young Children",[93],"2007-04",202,[3642],"Asthma",[3621],{"intervention":3645,"totalTrials":97,"cells":3646},"ND",{"EARLY_PHASE1":3647,"PHASE1":3649,"PHASE2":3651,"PHASE3":3653,"PHASE4":3655,"NA":3657},{"trials":3648,"activeCount":101},[],{"trials":3650,"activeCount":101},[],{"trials":3652,"activeCount":101},[],{"trials":3654,"activeCount":101},[],{"trials":3656,"activeCount":101},[],{"trials":3658,"activeCount":101},[3659],{"nctId":3660,"briefTitle":3661,"status":614,"phases":3662,"primaryCompletion":3663,"completion":3664,"start":667,"enrollment":2051,"conditions":3665,"interventions":3667},"NCT02376309","The Effect of Nandrolone Decanoate and Leucine on Muscle Loss",[93],"2016-08","2017-08",[3666],"Muscle Atrophy",[3645],{"intervention":3669,"totalTrials":97,"cells":3670},"Acipimox 250 mg Oral",{"EARLY_PHASE1":3671,"PHASE1":3673,"PHASE2":3675,"PHASE3":3677,"PHASE4":3679,"NA":3681},{"trials":3672,"activeCount":101},[],{"trials":3674,"activeCount":101},[],{"trials":3676,"activeCount":101},[],{"trials":3678,"activeCount":101},[],{"trials":3680,"activeCount":101},[],{"trials":3682,"activeCount":101},[3683],{"nctId":3684,"briefTitle":3685,"status":278,"phases":3686,"primaryCompletion":3687,"completion":3687,"start":3688,"enrollment":3689,"conditions":3690,"interventions":3692},"NCT06317142","Glucose and Glycogen Dynamics in Prediabetes",[],"2025-07","2024-02-20",45,[3691],"Pre Diabetes",[3669],{"intervention":3694,"totalTrials":97,"cells":3695},"COVID-19 vaccine",{"EARLY_PHASE1":3696,"PHASE1":3698,"PHASE2":3700,"PHASE3":3702,"PHASE4":3704,"NA":3706},{"trials":3697,"activeCount":101},[],{"trials":3699,"activeCount":101},[],{"trials":3701,"activeCount":101},[],{"trials":3703,"activeCount":101},[],{"trials":3705,"activeCount":101},[],{"trials":3707,"activeCount":101},[3708],{"nctId":3709,"briefTitle":3710,"status":756,"phases":3711,"primaryCompletion":3712,"completion":3712,"start":3713,"enrollment":974,"conditions":3714,"interventions":3715},"NCT04844346","Plant Stanol Esters and COVID-19 Vaccination Response",[93],"2022-01-11","2021-04-22",[25],[3694],{"intervention":3717,"totalTrials":97,"cells":3718},"Carnitor",{"EARLY_PHASE1":3719,"PHASE1":3721,"PHASE2":3723,"PHASE3":3725,"PHASE4":3727,"NA":3729},{"trials":3720,"activeCount":101},[],{"trials":3722,"activeCount":101},[],{"trials":3724,"activeCount":101},[],{"trials":3726,"activeCount":101},[],{"trials":3728,"activeCount":101},[],{"trials":3730,"activeCount":101},[3731],{"nctId":3732,"briefTitle":3733,"status":756,"phases":3734,"primaryCompletion":3735,"completion":3735,"start":3317,"enrollment":733,"conditions":3736,"interventions":3737},"NCT02722902","Carnitine Infusion and Insulin Resistance",[93],"2017-06",[1637],[3717],{"intervention":3739,"totalTrials":97,"cells":3740},"Hold",{"EARLY_PHASE1":3741,"PHASE1":3743,"PHASE2":3745,"PHASE3":3747,"PHASE4":3749,"NA":3751},{"trials":3742,"activeCount":101},[],{"trials":3744,"activeCount":101},[],{"trials":3746,"activeCount":101},[],{"trials":3748,"activeCount":101},[],{"trials":3750,"activeCount":101},[],{"trials":3752,"activeCount":101},[3753],{"nctId":3754,"briefTitle":3755,"status":278,"phases":3756,"primaryCompletion":3757,"completion":3758,"start":3759,"enrollment":3760,"conditions":3761,"interventions":3766},"NCT03288441","Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia",[],"2020-12-31","2021-12-31","2018-03-20",300,[3762,3763,3764,3765],"Hematologic Neoplasms","Thrombocytopenia","Anticoagulants","Platelet Aggregation Inhibitors",[3739,3767,3768,3769,3770,3771],"Prophylactic dose antithrombotic","Change antithrombotic Drug","Change platelet transfusion threshold","Full dose antithrombotics","Intermediate dose antithrombotic",{"intervention":3767,"totalTrials":97,"cells":3773},{"EARLY_PHASE1":3774,"PHASE1":3776,"PHASE2":3778,"PHASE3":3780,"PHASE4":3782,"NA":3784},{"trials":3775,"activeCount":101},[],{"trials":3777,"activeCount":101},[],{"trials":3779,"activeCount":101},[],{"trials":3781,"activeCount":101},[],{"trials":3783,"activeCount":101},[],{"trials":3785,"activeCount":101},[3786],{"nctId":3754,"briefTitle":3755,"status":278,"phases":3787,"primaryCompletion":3757,"completion":3758,"start":3759,"enrollment":3760,"conditions":3788,"interventions":3789},[],[3762,3763,3764,3765],[3739,3767,3768,3769,3770,3771],{"intervention":3768,"totalTrials":97,"cells":3791},{"EARLY_PHASE1":3792,"PHASE1":3794,"PHASE2":3796,"PHASE3":3798,"PHASE4":3800,"NA":3802},{"trials":3793,"activeCount":101},[],{"trials":3795,"activeCount":101},[],{"trials":3797,"activeCount":101},[],{"trials":3799,"activeCount":101},[],{"trials":3801,"activeCount":101},[],{"trials":3803,"activeCount":101},[3804],{"nctId":3754,"briefTitle":3755,"status":278,"phases":3805,"primaryCompletion":3757,"completion":3758,"start":3759,"enrollment":3760,"conditions":3806,"interventions":3807},[],[3762,3763,3764,3765],[3739,3767,3768,3769,3770,3771],{"intervention":3769,"totalTrials":97,"cells":3809},{"EARLY_PHASE1":3810,"PHASE1":3812,"PHASE2":3814,"PHASE3":3816,"PHASE4":3818,"NA":3820},{"trials":3811,"activeCount":101},[],{"trials":3813,"activeCount":101},[],{"trials":3815,"activeCount":101},[],{"trials":3817,"activeCount":101},[],{"trials":3819,"activeCount":101},[],{"trials":3821,"activeCount":101},[3822],{"nctId":3754,"briefTitle":3755,"status":278,"phases":3823,"primaryCompletion":3757,"completion":3758,"start":3759,"enrollment":3760,"conditions":3824,"interventions":3825},[],[3762,3763,3764,3765],[3739,3767,3768,3769,3770,3771],{"intervention":3770,"totalTrials":97,"cells":3827},{"EARLY_PHASE1":3828,"PHASE1":3830,"PHASE2":3832,"PHASE3":3834,"PHASE4":3836,"NA":3838},{"trials":3829,"activeCount":101},[],{"trials":3831,"activeCount":101},[],{"trials":3833,"activeCount":101},[],{"trials":3835,"activeCount":101},[],{"trials":3837,"activeCount":101},[],{"trials":3839,"activeCount":101},[3840],{"nctId":3754,"briefTitle":3755,"status":278,"phases":3841,"primaryCompletion":3757,"completion":3758,"start":3759,"enrollment":3760,"conditions":3842,"interventions":3843},[],[3762,3763,3764,3765],[3739,3767,3768,3769,3770,3771],{"intervention":3771,"totalTrials":97,"cells":3845},{"EARLY_PHASE1":3846,"PHASE1":3848,"PHASE2":3850,"PHASE3":3852,"PHASE4":3854,"NA":3856},{"trials":3847,"activeCount":101},[],{"trials":3849,"activeCount":101},[],{"trials":3851,"activeCount":101},[],{"trials":3853,"activeCount":101},[],{"trials":3855,"activeCount":101},[],{"trials":3857,"activeCount":101},[3858],{"nctId":3754,"briefTitle":3755,"status":278,"phases":3859,"primaryCompletion":3757,"completion":3758,"start":3759,"enrollment":3760,"conditions":3860,"interventions":3861},[],[3762,3763,3764,3765],[3739,3767,3768,3769,3770,3771],{"intervention":3863,"totalTrials":97,"cells":3864},"extrafine HFA-beclomethasone",{"EARLY_PHASE1":3865,"PHASE1":3867,"PHASE2":3869,"PHASE3":3871,"PHASE4":3873,"NA":3875},{"trials":3866,"activeCount":101},[],{"trials":3868,"activeCount":101},[],{"trials":3870,"activeCount":101},[],{"trials":3872,"activeCount":101},[],{"trials":3874,"activeCount":101},[],{"trials":3876,"activeCount":101},[3877],{"nctId":3878,"briefTitle":3879,"status":614,"phases":3880,"completion":1758,"start":3881,"enrollment":3882,"conditions":3883,"interventions":3884},"NCT00402207","The Anti-Inflammatory Effect of Extrafine HFA-Beclometasone Versus HFA-Fluticasone, by Means of Inflammometry",[93],"2005-08",33,[3642],[3863,3885],"HFA-fluticasone",{"intervention":3885,"totalTrials":97,"cells":3887},{"EARLY_PHASE1":3888,"PHASE1":3890,"PHASE2":3892,"PHASE3":3894,"PHASE4":3896,"NA":3898},{"trials":3889,"activeCount":101},[],{"trials":3891,"activeCount":101},[],{"trials":3893,"activeCount":101},[],{"trials":3895,"activeCount":101},[],{"trials":3897,"activeCount":101},[],{"trials":3899,"activeCount":101},[3900],{"nctId":3878,"briefTitle":3879,"status":614,"phases":3901,"completion":1758,"start":3881,"enrollment":3882,"conditions":3902,"interventions":3903},[93],[3642],[3863,3885],{"intervention":3905,"totalTrials":97,"cells":3906},"Pharmacological cardioversion - Flecainide",{"EARLY_PHASE1":3907,"PHASE1":3909,"PHASE2":3911,"PHASE3":3913,"PHASE4":3915,"NA":3917},{"trials":3908,"activeCount":101},[],{"trials":3910,"activeCount":101},[],{"trials":3912,"activeCount":101},[],{"trials":3914,"activeCount":101},[],{"trials":3916,"activeCount":101},[],{"trials":3918,"activeCount":101},[3919],{"nctId":3920,"briefTitle":3921,"status":614,"phases":3922,"primaryCompletion":758,"completion":3923,"start":1244,"enrollment":3924,"conditions":3925,"interventions":3926},"NCT02248753","Acute Cardioversion Versus Wait And See-approach for Symptomatic Atrial Fibrillation in the Emergency Department",[93],"2019-12",437,[30],[3905,3927,3928,3929,3930],"Metoprolol","Verapamil","Digoxin","Pharmacological cardioversion - Amiodarone",{"intervention":3927,"totalTrials":97,"cells":3932},{"EARLY_PHASE1":3933,"PHASE1":3935,"PHASE2":3937,"PHASE3":3939,"PHASE4":3941,"NA":3943},{"trials":3934,"activeCount":101},[],{"trials":3936,"activeCount":101},[],{"trials":3938,"activeCount":101},[],{"trials":3940,"activeCount":101},[],{"trials":3942,"activeCount":101},[],{"trials":3944,"activeCount":101},[3945],{"nctId":3920,"briefTitle":3921,"status":614,"phases":3946,"primaryCompletion":758,"completion":3923,"start":1244,"enrollment":3924,"conditions":3947,"interventions":3948},[93],[30],[3905,3927,3928,3929,3930],{"intervention":3928,"totalTrials":97,"cells":3950},{"EARLY_PHASE1":3951,"PHASE1":3953,"PHASE2":3955,"PHASE3":3957,"PHASE4":3959,"NA":3961},{"trials":3952,"activeCount":101},[],{"trials":3954,"activeCount":101},[],{"trials":3956,"activeCount":101},[],{"trials":3958,"activeCount":101},[],{"trials":3960,"activeCount":101},[],{"trials":3962,"activeCount":101},[3963],{"nctId":3920,"briefTitle":3921,"status":614,"phases":3964,"primaryCompletion":758,"completion":3923,"start":1244,"enrollment":3924,"conditions":3965,"interventions":3966},[93],[30],[3905,3927,3928,3929,3930],{"intervention":3929,"totalTrials":97,"cells":3968},{"EARLY_PHASE1":3969,"PHASE1":3971,"PHASE2":3973,"PHASE3":3975,"PHASE4":3977,"NA":3979},{"trials":3970,"activeCount":101},[],{"trials":3972,"activeCount":101},[],{"trials":3974,"activeCount":101},[],{"trials":3976,"activeCount":101},[],{"trials":3978,"activeCount":101},[],{"trials":3980,"activeCount":101},[3981],{"nctId":3920,"briefTitle":3921,"status":614,"phases":3982,"primaryCompletion":758,"completion":3923,"start":1244,"enrollment":3924,"conditions":3983,"interventions":3984},[93],[30],[3905,3927,3928,3929,3930],{"intervention":3930,"totalTrials":97,"cells":3986},{"EARLY_PHASE1":3987,"PHASE1":3989,"PHASE2":3991,"PHASE3":3993,"PHASE4":3995,"NA":3997},{"trials":3988,"activeCount":101},[],{"trials":3990,"activeCount":101},[],{"trials":3992,"activeCount":101},[],{"trials":3994,"activeCount":101},[],{"trials":3996,"activeCount":101},[],{"trials":3998,"activeCount":101},[3999],{"nctId":3920,"briefTitle":3921,"status":614,"phases":4000,"primaryCompletion":758,"completion":3923,"start":1244,"enrollment":3924,"conditions":4001,"interventions":4002},[93],[30],[3905,3927,3928,3929,3930],{"intervention":4004,"totalTrials":97,"cells":4005},"Whole-exome sequencing",{"EARLY_PHASE1":4006,"PHASE1":4008,"PHASE2":4010,"PHASE3":4012,"PHASE4":4014,"NA":4016},{"trials":4007,"activeCount":101},[],{"trials":4009,"activeCount":101},[],{"trials":4011,"activeCount":101},[],{"trials":4013,"activeCount":101},[],{"trials":4015,"activeCount":101},[],{"trials":4017,"activeCount":101},[4018],{"nctId":4019,"briefTitle":4020,"status":278,"phases":4021,"primaryCompletion":4022,"completion":4022,"start":1357,"enrollment":4023,"conditions":4024,"interventions":4027},"NCT02014961","Worm Study: Modifier Genes in Sudden Cardiac Death",[93],"2025-04",223,[4025,4026],"Brugada Syndrome","Long QT Syndrome 3",[4004],{"intervention":2954,"totalTrials":97,"cells":4029},{"EARLY_PHASE1":4030,"PHASE1":4032,"PHASE2":4034,"PHASE3":4036,"PHASE4":4038,"NA":4040},{"trials":4031,"activeCount":101},[],{"trials":4033,"activeCount":101},[],{"trials":4035,"activeCount":101},[],{"trials":4037,"activeCount":101},[],{"trials":4039,"activeCount":101},[],{"trials":4041,"activeCount":101},[4042],{"nctId":2947,"briefTitle":2948,"status":614,"phases":4043,"primaryCompletion":1244,"completion":901,"start":2950,"enrollment":2951,"conditions":4044,"interventions":4045},[93],[16,22],[2922,2954],{"intervention":4047,"totalTrials":97,"cells":4048},"Oxitriptan",{"EARLY_PHASE1":4049,"PHASE1":4051,"PHASE2":4053,"PHASE3":4055,"PHASE4":4057,"NA":4059},{"trials":4050,"activeCount":101},[],{"trials":4052,"activeCount":101},[],{"trials":4054,"activeCount":101},[],{"trials":4056,"activeCount":101},[],{"trials":4058,"activeCount":101},[],{"trials":4060,"activeCount":101},[4061],{"nctId":4062,"briefTitle":4063,"status":614,"phases":4064,"primaryCompletion":1087,"completion":1087,"start":4065,"enrollment":161,"conditions":4066,"interventions":4067},"NCT00731003","The Effect of Serotonergic Modulation on Intestinal Permeability and Visceral Hypersensitivity in Healthy Individuals and Irritable Bowel Syndrome (IBS) Patients",[93],"2009-04",[949],[4047],{"intervention":4069,"totalTrials":97,"cells":4070},"haloperidol 2mg",{"EARLY_PHASE1":4071,"PHASE1":4073,"PHASE2":4075,"PHASE3":4077,"PHASE4":4079,"NA":4081},{"trials":4072,"activeCount":101},[],{"trials":4074,"activeCount":101},[],{"trials":4076,"activeCount":101},[],{"trials":4078,"activeCount":101},[],{"trials":4080,"activeCount":101},[],{"trials":4082,"activeCount":101},[4083],{"nctId":4084,"briefTitle":4085,"status":614,"phases":4086,"primaryCompletion":4087,"completion":4088,"start":282,"enrollment":4089,"conditions":4090,"interventions":4092},"NCT06014606","Learning and Decision-making",[93],"2023-04-30","2023-08-16",150,[4091],"Motivation",[4069,4093],"propranolol 40mg",{"intervention":4093,"totalTrials":97,"cells":4095},{"EARLY_PHASE1":4096,"PHASE1":4098,"PHASE2":4100,"PHASE3":4102,"PHASE4":4104,"NA":4106},{"trials":4097,"activeCount":101},[],{"trials":4099,"activeCount":101},[],{"trials":4101,"activeCount":101},[],{"trials":4103,"activeCount":101},[],{"trials":4105,"activeCount":101},[],{"trials":4107,"activeCount":101},[4108],{"nctId":4084,"briefTitle":4085,"status":614,"phases":4109,"primaryCompletion":4087,"completion":4088,"start":282,"enrollment":4089,"conditions":4110,"interventions":4111},[93],[4091],[4069,4093],{"intervention":4113,"totalTrials":97,"cells":4114},"Three different mixture of acetate, butyrate and propionate and palcebo",{"EARLY_PHASE1":4115,"PHASE1":4117,"PHASE2":4119,"PHASE3":4121,"PHASE4":4123,"NA":4125},{"trials":4116,"activeCount":101},[],{"trials":4118,"activeCount":101},[],{"trials":4120,"activeCount":101},[],{"trials":4122,"activeCount":101},[],{"trials":4124,"activeCount":101},[],{"trials":4126,"activeCount":101},[4127],{"nctId":4128,"briefTitle":4129,"status":614,"phases":4130,"primaryCompletion":4131,"completion":4131,"start":2188,"enrollment":2143,"conditions":4132,"interventions":4133},"NCT01983046","Rectal Short Chain Fatty Acids Combinations and Substrate and Energy Metabolism",[93],"2014-02",[16,1404],[4113],{"intervention":4135,"totalTrials":97,"cells":4136},"Pantoprazole",{"EARLY_PHASE1":4137,"PHASE1":4139,"PHASE2":4141,"PHASE3":4143,"PHASE4":4145,"NA":4147},{"trials":4138,"activeCount":101},[],{"trials":4140,"activeCount":101},[],{"trials":4142,"activeCount":101},[],{"trials":4144,"activeCount":101},[],{"trials":4146,"activeCount":101},[],{"trials":4148,"activeCount":101},[4149],{"nctId":4150,"briefTitle":4151,"status":278,"phases":4152,"primaryCompletion":1130,"completion":1130,"start":2941,"enrollment":974,"conditions":4153,"interventions":4155},"NCT01524757","Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis",[93],[4154],"Hemochromatosis",[4135]]